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Abstract 
Bioisosteric replacements are used in drug design during lead generation and optimization 
processes with the aim to replace one functional group of a known molecule by another 
while retaining biological activity. The reason to use bioisosteric replacements are 
typically to optimize bioavailability or reducing toxicity. Phosphate groups represent a 
paradigm to study bioisosteric replacements. Protein-phosphate interaction plays a critical 
role during molecular recognition processes, and for example kinases represent one of the 
largest families of drug targets. However, some challenges exclude phosphate as a 
promising lead-like building block: i) charged phosphates do not cross molecular 
membranes; ii) some widely expressed proteins such as phosphatases easily hydrolyze 
phosphoric acid esters, which lead phosphate-containing ligands to lose their binding 
affinities before reaching their biological targets; iii) introduction of phosphate groups to 
parent scaffold is not easy. 
In the first part of the thesis work, I designed and implemented a computational 
protocol to mine information about phosphate structural replacements deposited in the 
Protein Data Bank. I constructed 116, 314, 271, and 42 sets of superimposed proteins 
where each set contains a reference protein to either POP, AMP, ADP, or ATP as well as a 
certain number of non-nucleotide ligands. 929 of such ligands are under study. The 
chemotypes that came out as structural replacements are diverse, ranging from common 
phosphate isosteres such as carboxyl, amide and squaramide to more surprising moieties 
such as benzoxaborole and aromatic ring systems. I exemplified some novel examples and 
interpreted the mechanism behind them. Local structural replacements are circumstance 
dependent: one chemical group valid in certain set-up cannot necessarily guarantee the 
success of another. The data from the study is available at 
http://86.50.168.121/phosphates_LSR.php. 
In the second part, I synthesized fifteen compounds retaining the adenosine moieties 
and bearing bioisosteric replacements of the phosphate at the ribose 5'-oxygen to test their 
stability toward human macro domain protein 1. These compounds are composed of either 
a squaryldiamide or an amide group as the bioisosteric replacement and/or as a linker. To 
these groups a variety of substituents were attached: phenyl, benzyl, pyridyl, carboxyl, 
hydroxy and tetrazolyl. Biological evaluation using differential scanning fluorimetry 
showed that four compounds stabilized human MDO1 at levels comparable to ADP and 
one at level comparable to AMP. Virtual screening was also run to identify MDO1 
binding ligands. Among 20,000 FIMM database lead-like molecules, 39 compounds were 
selected for testing and eleven compounds found active based on ADPr and Poly-ADPr 
competition binding assay. The assay is however not well validated and a second 
confirmatory assay was conducted using calorimetry. To the best of my knowledge, this is 
the first report of non-endogenous ligands of the human MDO1. 
Altogether, this thesis highlights the versatility of molecular recognition processes that 
accompanies chemical replacements in compounds; this in turns shows the limits of the 
concepts of molecular similarity and “classical” bioisosterism that are based on the 
conservation of molecular interactions. 
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monophosphate 
ADP  Adenosine-5'-diphosphate 
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ribose 
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Arginine Arg R Lysine Lys K 
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Glutamic acid Glu E Serine Ser S 
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1 Introduction 
Medicinal chemists face challenges in developing small molecules with high potency as 
well as other characteristics such as the capability to be delivered to biological targets 
(bioavailability), reduced toxicity, unwanted effects and increase the permeability (George 
& Nathan, 2013), together with chemical and metabolic stability and solubility. Often, 
when a compound is available, it needs to be modified and optimized for one or the other 
of these objectives in a process named lead optimization. Bioisosteric replacement is one 
of the main strategies to perform optimization. Bioisosteric replacements are fulfilled by 
replacing one functional group of a known molecule by other functional group resulting in 
a similar biological/physicochemical property. As stated by the IUPAC, “A bioisostere is 
a compound resulting from the exchange of an atom or group of atoms with another, 
broadly similar, atom or group of atoms.” (http://goldbook.iupac.org/BT06798.html) 
 
Among the variety of chemical moieties that have been studied by medicinal chemists 
over the last century, phosphate groups are one of the most urgently demanded since there 
is a considerable amount of proteins whose endogenous ligand contains phosphate groups. 
For example, the single protein family of kinases accounts for about 1.7% of the proteins 
encoded by the human genome (Manning, et al., 2002). In medicinal chemistry, phosphate 
groups need to be replaced for several reasons: (1) the diffusion of negative charged 
phosphates across the highly hydrophobic cell membrane is highly unfavorable (Smith, et 
al., 2003); (2) some enzymes, phosphatases for example, hydrolyze phosphoric acid ester 
very easily, which probably let phosphate containing ligands to lose the majority of 
binding affinities without approaching their biological targets; (3) introduction of 
phosphate groups into parent scaffold or compounds is challenging in terms of chemistry 
(Zhao, et al., 2012). 
 
In this thesis, taking the example of phosphate groups in particular, as well as 1',5'- 
bonded ribose, we investigated how they can be replaced by other chemotypes. We 
constructed a fully automated workflow to extract protein ligand structural information 
deposited in Protein Data Bank (PDB) (Berman, 2000) to automatically extract local 
structural replacements of the phosphate and ribose groups that were found in AMP, ADP, 
ATP and POP binding proteins. This data allows us to consider the different mechanisms 
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as well as replacement possibilities for phosphate and ribose. While this data does not take 
into account biological activity, it does provide key information about the mechanisms 
beyond the structural replacements. The data is made available to the research community 
through a website located at http: http://86.50.168.121/bioisosteres.php. 
 
Secondly, phosphate (bio)isosterim is analyzed directly by synthesizing a small library 
of 15 ADPr analogs, belonging to two series that bear classical bioisosteric replacements 
in their phosphate moieties and were tested towards an human ADP-ribose (ADPr) 
binding protein, macro domain protein 1. The MDO1 has to date no synthetic compounds 
that could be used for biochemical studies or to be used as a template to construct a 
fluorescent biochemical probe for screening or molecular imaging. Due to the absence of 
such compounds, the functions of human MDO1 are still poorly understood. Recent 
findings have implicated human MDO1 has been implicated in multiple cancers, such as 
ovarian carcinoma (Tian, et al., 2009), breast carcinoma (Zhao, et al., 2010), colorectal 
carcinoma (Han et al., 2011), and acute leukemia (Imagama, et al., 2007). The MDO1 is 
able to hydrolyze O-acetyl-ADP-ribose and four crystal structures exists that show a 
complex of the unliganded human MDO1 (PDB code: 2X47; Chen et al., 2011) as well as 
the related parasitic MDO1 (PDB code: 2BFQ, 2BFR), (Karras, et al., 2005) and human 
MDO2 (PDB code: 4IQY),(Jankevicius, et al., 2013) these latter being bound with ADPr. 
Five compounds among fifteen were successfully found to stabilize MDO1 in millimolar 
concentrations using differential scanning fluorimetry, which relates to a binding constant 
in the μM range. 
 
Finally, I present results about virtual screening of the human MDO1 protein. Forty-
three ligands were screened using competitive assay and isothermal titration calorimetry 
(ITC) and differential scanning calorimetry (DSC). Nine compounds were found active 
using competition assay, however by an assay not fully validated. DSC was used to retest 
the compounds but at a concentration probably too low for detection. As a perspective, 
these experiments need to be conducted again. 
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2 Review of the literature 
This literature review is based on three sections: 1) fundamental concepts about molecular 
recognition; 2) the concept of bioisosteric replacements including phosphate bioisosteres; 
3) the concept of molecular similarity in a computational perspective. A number of 
excellent reviews have been used as a source to initiate the search of articles in these fields. 
For molecular interactions, I am referring to perspective article “A medicinal chemist's 
guide to molecular interactions” (Bissantz, et al., 2010). For phosphate bioisosterism, 
there are three reviews: “Phosphate isosteres in medicinal chemistry” (Rye and Baell, 
2005), “The use of phosphate bioisosteres in medicinal chemistry and chemical biology” 
(Elliott et al., 2012) and “Synthesis of α-brominated phosphonates and their application as 
phosphate bioisosteres” (Downey and Cairo, 2014). For general bioisostere applications in 
drug design, a short course-based article “Synopsis of Some Recent Tactical Applications 
of Bioisosteres in Drug Design” was cited (Meanwell, 2011). The textbook “Bioisosteres 
in medicinal chemistry” from Nathan Brown was also a knowledgeable source of 
inspiration. 
. 
2.1 Molecular recognition 
It is the recognition of ligands by their host molecules, typically proteins, which drives 
biological processes. Therefore, understanding this process is crucial to life sciences. 
Furthermore, molecular recognition is critical to structure-based drug design that attempts 
to make compounds with optimal molecular interactions. 
 
Molecular recognition processes involve agonists or antagonists with receptors, substrates 
or inhibitors with enzymes, antigens to antibodies. In 1894, Emil Fischer suggested the 
“lock-and-key” theory to demonstrate the ligand-protein interaction mechanism. Later, it 
was observed that active site of the protein is reshaped by interactions with the ligands and 
vice versa, so both the protein active site and the ligand itself rearranged comparing to 
original state during molecular recognition. The “lock-and-key” theory is no longer 
sufficient to know how the key fits into the lock. Accordingly, in 1958, Daniel Koshland 
proposed the “induced-fit model”, which is more appropriate (Jorgensen, 1991) to portray 
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how ligand and protein may adjust their conformation(s) to achieve an overall “best-fit” 
(Wei et al., 2004). Today, the importance of water molecules is starting to be recognized 
and addressed. Two major roles are envisioned to water molecules in ligand binding. The 
first role is to stabilize a protein-ligand complex through creating a hydrogen bonding 
network. The second one is the ability of water molecules to be displaced upon ligand 
binding, and there are costs to desolvate both protein and ligand. 
2.1.1 Ligand-receptor interactions 
2.1.1.1 Thermodynamics of ligand binding 
Binding processes can be described using a simple thermodynamic equation. Reversible 
binding processes of a ligand (L) binding to a protein (receptor, R) is in equilibrium when 
concentrations remain unchanged. 
 
The process is dynamic and depends on the association rate (   ) and dissociation rate 
(    ). 
The equilibrium dissociation constant    is then defined as:   = 
   
    
 
Sometimes the binding is assessed in relation to displacement of a competitor, in which 
case inhibition constant    is measured. 
 
 
Spontaneous processes takes place only when they are related with negative Gibbs free 
energy. For reversible binding processes at equilibrium, the binding affinity or the molar 
Gibbs free energy ΔG is related to the dissociation constant    by: 
          
  
  
          
in which R is the ideal gas constant, T the absolute temperature and the standard reference 
concentration    = 1 mol/L, ΔH is the enthalpic change and TΔS is the entropic term. 
 
Depending on the sign and relative weight of the ∆H and ∆S components, one specific 
 6 
 
binding process (i.e. a negative   ) can be either enthalpy- or entropy-driven. 
 
 ∆H can be roughly approximated as the difference between the energy used to 
break bonds in a chemical reaction and the energy gained by the formation of new 
chemical bonds in the reaction. It includes intramolecular and intermolecular weak 
interactions (inside protein; protein to ligand; protein to solvent; solvent to solvent; 
etc.), as well as the costs of solvating and desolvating the protein and the ligand. 
 
 ∆S, the entropy change, qualifies the molecular energy dispersed in a process. ∆S 
represents roughly the loss of flexibility of the ligand; the loss of flexibility of the 
protein; and the rearrangements in the solvent network; etc. 
 
Experimentally, only ΔG and ΔH can be measured and can be used to determine ΔS. ΔG is 
measured from    with binding (or functional) assays; ΔH is characterized using 
isothermal titration calorimetry (ITC). Such data is for example available together with 
structural protein-ligand data about the complexes in a freely available database, 
SCORPIO (Olsson et al., 2008). To date, the new version SCORPIO 2.0 holds 30 different 
proteins, 173 ligands and 118 unique protein-ligand complexes. The aim of this database is 
to relate structure to thermodynamics. 
 
In computational drug discovery, a phenomenon has been observed based on comparing 
the TΔS to ΔH. Firstly, binding affinity (  ) is not correlated to either enthalpy or entropy 
separately (Reynolds and Holloway, 2011). Furthermore, it is empirically observed that 
when considering analogous series of compounds, increase of ΔH are related to decrease 
of TΔS. As a consequence, ligands with the most favorable entropies of binding actually 
have very unfavorable enthalpies of binding, while reciprocally the most favorable 
enthalpies have negative entropies of binding. This is very important point because the 
majority of structure-based drug design software use interaction energies for ligand pose 
assembly and ranking. At this stage, these energies are most closely comparable to 
enthalpies only. Few docking programs include entropy items and none is accurately 
computed (Hanzi et al., 2014). 
 
The estimation of ΔG is difficult especially since ΔH and TΔS are large compared to ΔG. 
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Large uncertainties in enthalpy measurements can yield apparent (but false) entropy-
enthalpy compensation (Chodera and Mobley, 2013). In case the entropy-enthalpy 
compensation does occur, the main physical reasons are solvent reorganization and 
receptor flexibility, while they seldom are relevant to the conformational restriction of free 
energy decomposition. 
2.1.1.2 Solvent effects in protein-ligand recognition 
The hydrophobicity plays key roles in molecular recognition. Hydrophobicity (from the 
Greek word hydro, water; and phobic, fearing), describes the repulsion leading to 
exclusion between water and nonpolar substances. The hydrophobic effect involves many 
factors with different enthalpic and entropic contributions and it is not yet fully understood 
(Biela et al., 2013). Solutes including apolar solutes are surrounded by ordered water 
molecules, usually as a “cage”. At the molecular level, it is entropically favorable that the 
contact areas of these apolar solutes with ordered water are minimized and the amount of 
free water maximized, leading to the phenomenon of hydrophobicity. The hydrophobic 
effect explains why soluble proteins fold with a hydrophobic core and hydrophilic outer 
surface (Dill et al., 2008), and why the core of a protein is reachable for hydrophobic 
ligands (Whitesides and Krishnamurthy, 2005). Since receptors and ligands predominately 
consist of carbon and hydrogen atoms, the importance of the hydrophobic effect is 
considerable in biomolecular recognition. 
 
The solvent is referred to as bulk water. Bulk water refers to water molecules that are 
surrounding the protein or often loosely trapped in the protein binding site. However, 
water molecules, and ions, can also affect directly molecular recognition. Water molecules 
can mediate or bridge the contact between ligand and receptor. When these water 
molecules are observed in X-ray crystallography they are named structural water 
molecules. Structural water molecules affect the binding through reshaping the protein 
surface or by mediating the binding with hydrogen bonds. In general, ligands that use 
tightly bound water bridges are smaller, less lipophilic, and less planar and have higher 
ligand efficiency indices (García-Sosa, 2013). Water molecules have also been found to be 
important in protein-protein interactions (Rajagopala et al., 2014),(Li et al., 2012). 
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The process of ligand recognition involves desolvation and solvation events, both at the 
ligand and receptor site. Some molecules are favorable to displace, some are not. Bulk 
water molecules are readily replaced since the release of ordered water is entropy-
favorable to ligand-receptor binding. Buried water molecules can however be sometimes 
be favorable to displace, most often when they are forming few hydrogen bonds (Bissantz 
et al., 2010); but tetracoordinated waters are however difficult to displace. Conserved 
water molecules are replaceable, but this replacement requires very high surrogates of the 
interaction in terms of geometry because the enthalpy loss might not be paid off by 
entropy. An example of favorable displacement of water molecules is provided by HIV-1 
protease inhibitors, cyclic ureas, where a cyclic ligand obtains an increase in hydrophobic 
interactions as well as beneficial rigidity for binding compared to the noncyclic, hydrated 
ligand complexes (Lam et al., 1994). Another example is carbonic anhydrase. Among a 
series of structurally homologous heterocyclic aromatic sulfonamides binding to carbonic 
anhydrase, changes in the number and organization of water molecules localized in the 
active site, rather than the release of structured water from the apposed hydrophobic 
surfaces, determine the thermodynamics of binding of these ligands to the protein (Snyder 
et al., 2011). In this example, gain in binding affinity is therefore enthalpy-driven. 
 
Computational prediction of the location and thermodynamic properties of water 
molecules has been recognized of key importance in drug discovery (Yang, et al., 2014). 
The goal is to identify water molecules that are favorable or unfavorable to displace, and 
use this information to grow ligand parts. Computational methods based on long 
molecular dynamic simulations of water molecules with a restrained protein are for 
example used in WaterMap (Schrödinger Ldt) (Abel et al., 2008), a commercial suite. It is 
also able to differentially displace and retain specific water molecules in protein binding 
sites (Young et al., 2007). A free software based on molecular dynamics, WATsite, has 
been developed (Hu and Lill, 2014). Molecular docking protocols have also been used and 
they claim good accuracies (70-80%) in recreating the position of structural water 
molecules (Ross, et al., 2012). 
 
Other protocols have for example used a geometrical scoring function named WaterScore 
(García-Sosa, et al., 2003), together with a ligand-superposition-based pharmacophore to 
distinguish bound and displaceable water in the protein binding sites of thymidine kinase 
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and poly-(ADP-ribose) polymerase (Lloyd et al., 2004). Other protocols have used the 
HINT free energy scoring function (Eugene Kellogg and Abraham, 2000) and geometric 
descriptor Rank (Kellogg and Chen, 2004) to predict crystallographic water molecules 
with accuracies of 86% (training) and 92% (test) (Amadasi et al., 2008). JAWS (Michel, et 
al., 2009) is a Monte Carlo simulation and statistical thermodynamics methodology to 
determine the position of water molecules in the binding site of a protein or protein-ligand 
complex. 
2.1.2 Specific intermolecular interactions (noncovalent interactions) 
When a ligand interacts with a receptor, a number of forces are responsible for the 
interaction. Though a very weak interaction individually compared to a covalent bond, 
cumulatively noncovalent bonds are fundamental to ligand protein interaction. 
 
Interactions originate from the permanent or partial charges carried by atoms. When 
studied using classical mechanics, all electronic effects are combined and each atom is 
assimilated to a single particle and each particle assigned a radius and a net charge. The 
net charge represents its formal charge, the presence of an electron lone pairs, and the 
delocalization of electrons across bonds. Formal charges are the result of loss or gain of a 
proton H
+
 (i.e. a hydrogen atom that has “lost” an electron, for example in the dissociation 
–COOH COO- + H+, the –COO- group bears an “additional” electron as a result of 
the dissociation). Partial charges are due to excess of electrons (lone pairs) or to electronic 
delocalization. There are two types of electronic delocalization across bonds: inductive 
effects, when two bonded atoms differ in electronegativity; and resonance effects, the 
delocalization of electrons across conjugated systems. Dipoles, that may be permanent or 
temporary (induced), are created by the presence of several charged centers in a molecule. 
For example, the peptide bond has a permanent dipole that is oriented from the amide 
nitrogen to the carbonyl and 1/3 of a permanent full charge. 
 
The principal types of interactions are summarized in Table 1. Columbic interactions are 
attractive or repulsive interactions formed by two charged groups and follow Coulomb's 
law. Dipole-dipole interactions result when the partially negative portion of one of a dipole 
approaches the partially positive portion of the second dipole while they are aligned in 
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space. Hydrogen bonds (H-bonds) are a specific type of dipole-dipole attraction that 
involves the interaction between a partially positively charged hydrogen atoms to a highly 
electronegative atom such as a partially negatively charged oxygen, nitrogen, sulfur, or 
fluorine atom. The Van der Waals interaction includes the Keesom force (attractive or 
repulsive forces between molecules other than those due to covalent bonds), Debye force 
(attractive interaction between a permanent multipole on one molecule with an induced 
multipole on another) and London dispersion force (quantum-induced instantaneous 
polarization or instantaneous dipole-induced dipole force). The order of bond strength is 
as following: ionic  H-bond   dipole-dipole  van der Waals. 
 
A potential function or force field in molecular modeling, calculates the molecular 
system's potential energy (E) in a given conformation as a sum of individual energy terms. 
 
  =           +              
 
where           consists of three main terms:           =       +        +           and 
             consists of two terms:              =                +               
 
In CHARMM force field               or     is simplified as: 
          
   
   
   
      
   
   
   
   
         
 
      is given as: 
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Table 1 Molecular interactions 
 
Chemical bond Strength 
Formula to model the force of 
interaction (force) 
Description 
Covalent bond 100 kcal/mol 
               
   
     
 
                
   
     
 
                  
         
       
     
Geometry (length, angles) 
depends on atom types and 
hybridization 
Electrostatic interaction 
(Coulombic) 
5-40 kcal/mol    
 
    
      
  
 
      : signed magnitudes 
of the charges, r: distance 
between the charges 
non-directional 
van der 
Waals 
Keesom 
force 
0.5-2 kcal/mol 
   
    
   
 
      
   
      
 
m: charge per length, 
    permitivity of free 
space,      dielectric 
constant of surrounding 
material,     Boltzmann 
constant and r: distance 
between molecules 
Debye force    
   
   
      
   
   
 α: polarizability 
London 
dispersion 
force 
<1 kcal/mol     
    
   
 
I: the first ionization 
energy of each molecule 
2.1.2.1 Hydrogen bonds 
Hydrogen bonds are the most important specific interactions in biological recognition 
processes. When designing compounds, hydrogen bonding should be spatially well 
positioned otherwise they become detrimental to activity. A hydrogen bond is an 
interaction between a proton donor (D) (electronegative atom, especially nitrogen or 
oxygen) and a proton acceptor or lone pair carrier (A). An aromatic ring can serve as a 
hydrogen acceptor because an electron-rich π system above and below the benzene ring 
hosts a partial negative charge (Du et al., 2013). Hydrogen bonds have energies in the 1-12 
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kcal mol
-1
. 
 
Hybridization of the D and A atoms and especially their ionic character ΔpKa are the 
determinants of hydrogen bonds strength: When ΔpKa approaches to zero, the strength of 
hydrogen bond gets close to maximum (Gilli et al., 2009). The strength of hydrogen bonds 
is reflected in the geometries (directionality) and interatomic distances among the donor, 
acceptor and hydrogen atoms. Salt bridges where the acceptor is acidic and the donor a 
base are an example of strong charged reinforced hydrogen bonds and are very 
constrained both in terms of distance and geometry. 
 
In terms of distance, the sum of van der Waals radius between two electronegative atoms 
defines the length of hydrogen bond, but some have been observed to be shorter. Typical 
length is for example, the distance between amide C=O and OH which has a median about 
2.75 Å in Cambridge Structural Database (CSD), with amide NH donors, the median 
distance increases to about 2.9 Å (Bissantz et al., 2010). 
 
In terms of geometry, hydrogen bonds are generally formed along the direction of free 
electron pairs of the acceptor atoms. In theory, the preferred angle C=O   H is 120°, which 
corresponds to the lone pair direction of the carbonyl. Of important note, hydrogen bond 
can be bifurcated.  
  
2.1.2.2 Halogen bonds 
Halogen bonds are comparable to hydrogen bonds, but the halogen atom is shared between 
a donor D and an acceptor A. Halogen bonds were discovered in 1986: in crystallographic 
environment, the electrophiles, such as metal ions, tend to approach halogens of C-X (X = 
CI, Br, I) at an angle of  100° (“side-on”), while nucleophiles, such as oxygen and 
nitrogen, at  165° (“head-on”) (Ramasubbu, et al., 1986). Halogen bonds involve a 
negative site, e.g. a lone pair of a Lewis base and the positive electrostatic potential on the 
outermost portions of covalently-bonded halogen atoms, termed as σ-hole (Politzer et al., 
2007),(Wolters et al., 2014). σ-hole is due to the atom's charge distribution anisotropy 
(Politzer, et al., 2013). 
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Halogen bonds are important to medicinal chemistry since many drugs are halogenated 
molecules. An example of halogen bonds is given by phosphodiesterase type 5 (PDE5) 
inhibitors, shown in Figure 1. The halogens interact with the residue Tyr612 and and one 
water molecule involved in a network. An increased IC50 ranged from 90.0 nM with 
fluorine (2, Fig.1), 35.9 nM with chlorine (3, Fig.1), 13.3 nM with bromine (4, Fig.1) to 
7.2 nM with iodine (5, Fig.1) of inhibitor, respectively while reference (1, Fig.1) being 
51.8 nM when it is hydrogen atom (Ren et al., 2014). 
 
 
Figure 1 Structures of five inhibitors and their complexes with the catalytic domain of 
PDE5. (A) The detailed interactions between 4 and PDE5. (B) The 
superimposition of 2 (yellow), 3(slate), 4 (cyan) by fitting the coordinates of 
proteins of three complex structures PDB-code: 3SHY, 3SHZ, 3SIE individually. (C) 
Chemical structures of the five inhibitors. Adapted from Ren et al., 2014. 
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2.1.2.3 π interactions 
Interactions involving π systems are critical to protein-ligand recognition since the side 
chains of aryl-containing amino acid such as Trp, Phe, Tyr, and His are often exposed to 
binding site. In addition, aryl moiety is often present in small molecules. Several π 
interactions include π-π stacking, alkyl-aryl, and cation/anion-π. The electrostatic theory in 
polarized π systems can be used to explain these interactions (Martinez and Iverson, 2012). 
The prototype of π-π system is the benzene dimer. In the π system of benzene, a partial 
negative π electron density occurs above and below the plane of the ring and a partial 
positive charge on the periphery of the rings. 
 
There are three types of π-π stacking interactions (Fig. 2). The parallel displaced and T-
shaped modes are the most stable conformations. This charge distribution leads to 
favorable interactions in the T-shaped and parallel displaced conformers, but to less 
favored interactions in the stacked one.(Waters, 2002) However, it becomes favorable if 
the polarity of one ring is reversed by the addition of electron withdrawing substituents. In 
protein structures, the parallel-displaced arrangement is 0.5-0.75 kcal/mol more stable 
than T-shaped (McGaughey, 1998). 
 
Figure 2 Geometries, quadrupole moments of typical π–π aromatic interactions. Adapted 
from Matthews et al., 2014. 
 
Cation-π interaction is non-covalent intermolecular interaction between the face of 
electron-rich π system and cation. Energetically, a cation-π interaction is comparable to or 
stronger than a typical hydrogen bond. Theoretical studies also indicated typical cation-π 
interaction energies of about 5.5 kcal/mol in an exposed aqueous media (Gallivan and 
Dougherty, 2000). In the case of ligand-receptor interaction, the π system usually comes 
from the residue of aryl containing amino acids, while cations are supplied by the 
protonated amines (RNH3
+
), quaternary ammonium ions, sulfonium ions and carbocations 
(Dougherty, 2007). Many examples of binding sites rich in aromatic amino acids and 
 15 
 
where cation-π interactions occur can be found, such as the GABA receptor (Lummis et al., 
2005) or the D2 dopamine receptor (Torrice et al., 2009), (Zacharias, 2002), (Dougherty, 
2013). 
 
Anion-π interaction is an interaction, where a negatively charged group with the positive 
electrostatic potential on the ring edge of an aromatic group forms a favorable anion-
quadrupole interaction (Jackson et al., 2007), (Schottel, et al., 2008). Philip and coworkers 
studied anion-π pairs and found them both in α helices and β strands in Protein Data Bank 
(Philip et al., 2011). An example of molecular recognition is given by Schwans et al. who 
demonstrated that anion-aromatic interactions between the anionic Asp38 and Phe54 and 
Phe116 were used to position the general base in the ketosteroid isomerase active site 
(Schwans et al., 2013). 
2.2 Chemical replacement strategies 
2.2.1 The Structure-Property Principle 
The Structure-Property Principle is the cornerstone of medicinal chemistry. It states that 
similar molecules have similar activities. It is used by medicinal chemists to suggest 
similar candidate compounds with certain activity; to assess how similar a candidate is 
comparing to commercially available one in order to avoid the intellectual property 
conflict; and to investigate whether structurally dissimilar candidates are also reliable 
leads and what is the mechanism behind these novel structures (Maggiora et al., 2013). 
The marketed drugs are mimics of endogenous molecules to varying degrees. This may 
spur one to learn from these natural products because most of them were readily 
recognized by macromolecules with decent binding affinity, such ADP analogs. 
2.2.1.1 Defining molecular similarity 
Depending on individual perspective, “similarity” has many different meanings et al., 
2004), (Willett, 2013). One aspect of “similarity” is based on physicochemical 
characteristics, such as log P, boiling point, molecular weight, solubility, electron density 
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and dipole moment. Another point of view is to describe molecular similarity based on 
features such as molecular fingerprints, ring system and topology, as is done in 
chemoinformatics. A third viewpoint is to consider similar compounds with approximately 
the same atomic constituents, functional groups, backbone, or ring systems. Not very often, 
compounds that can be obtained by a single step of synthesis may be considered similar. 
Böhm et al. thought two scaffolds can be different if they were synthesized using different 
synthetic routes, no matter how small the change might be (Böhm, et al., 2004). Biological 
similarity is another concept that disregards the structural features of the compounds; 
instead, it relates the activity of compounds against a panel of biological targets. 
2.2.1.2 Activity cliffs 
Structure-activity relationship (SAR) discontinuity, i.e., defined as pairs of structurally 
similar compounds with a significant difference in potency, has been referred to as activity 
cliffs (Maggiora, 2006). On average, one in five compounds was shown to be involved in 
activity cliff (Sisay, et al., 2009). This makes SAR prediction difficult, but on the other 
hand, activity cliffs found in compound data sets might be a potential starting point of 
novel compounds (Dimova et al., 2013). One difficulty in predicting the effect of 
modifications arises since binding modes of structurally similar ligands may vary. Based 
on an investigation of the PDB, Boström et al. attribute this uncertainty to reorganization 
of water molecules and side-chain but seldom backbone movements of protein (Boström, 
et al., 2006). 
2.2.2 Isosteres and bioisosteres 
Bioisosteric replacements are one of the important strategies in the design of new 
molecules in medicinal chemistry, often utilized in lead optimization process with the aim 
of mimicking or improving properties such as pharmacokinetics, metabolism, solubility, 
or reducing side effects while keeping or improving potency. 
2.2.2.1 The development of bioisosterism 
About one century ago, the term isosterism was coined by Irving Langmuir (Langmuir, 
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1919). His work focused on the relationships between electronic configuration and 
physical properties. For example, carbon monoxide and the cyanide ion have the same 
number of electrons in their valence shell and are similar in term of physical properties, 
such as critical pressure, critical temperature, viscosity, magnetic susceptibility, but not 
freezing point. Later, H. G. Grimm introduced the concept of pseudoatom, which 
hypothesizes similar properties for atoms with an added hydrogen to atoms with the next 
atomic number. Hence, OH is isosteric with F.  
 
Following the work of Erlenmeyer, Thornber proposed a general definition of bioisoteres: 
“Bioisosteres are groups or molecules which have chemical and physical similarities 
producing broadly similar biological properties” (Thornber, 1979). He thought eight 
aspects can be considered when one tries to identify structural alterations: size, shape, 
electronic distribution, lipid solubility, water solubility, pKa, chemical reactivity and 
hydrogen bonding capacity. It was later stated that bioisosteres are not necessarily alike in 
their physical but biological properties (Burger, 1991). 
2.2.2.2 Phosphate isosteres 
At biological pH (pH 7.4), phosphate is predominately charged, with pKa1 1.54 and pKa2 
6.31. Phosphate shows tetrahedral molecular geometry. Instinctively, bioisosteres of 
phosphate should be fragments that are similar to phosphate in terms of charge, hydrogen 
bonding and geometry. Typical phosphate bioisosteric replacements have been reviewed 
by Elliott et al. (Elliott et al., 2012) and Rye et al. (Rye and Baell, 2005). These are 
phosphonates, carboxylates and malonates (Desvergnes et al., 2012), sulfamates (Moreau 
et al., 2013), squaramides and squaric acids (Niewiadomski et al., 2010), boron-containing 
fragments (Albers et al., 2011), and phosphorothioates (Liu et al., 2008). Many studies 
have explored different types of replacements for phosphate. Some of these examples are 
discussed below. 
Phosphorus-containing isosteres 
Structurally, the simplest way to obtain a phosphate bioisostere is to replace the bridging 
oxygen of a phosphate by methylene, leading to the phosphonate moiety. An example of a 
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phosphonate replacement is given by the study of He et al. where two series of 
metabolically stable phosphonate bearing analogs were synthesized (He et al., 2011). All 
analogs (Fig. 3) bind the same four-phosphate-adaptor protein 1 pleckstrin homology 
domain, where natural compound PtdIns(4)P do with improved Kd from 0.46 μM 
(compound 6, Fig.3) to 0.39 μM (compounds 9 and 10, Fig.3) and 0.25 μM (7, 8, Fig.3). 
 
 
Figure 3 The metabolically stable analogs PtdIns(4)P-MP (7-8) and PtdIns(4)P-PT (9-10) 
of PtdIns(4)P (6). Adapted from J. He et al., 2011. 
  
The phosphorus-carbon bond in phosphonates is more stable to hydrolysis than 
phosphorus-oxygen in diphosphate. Phosphonate compounds have pKa that varies between 
6.7 and 8.4. (Table 2) Though the stability of phosphates is improved by phosphonate, 
phosphonate is not a perfect bioisosteric replacement of phosphates in terms of pKa. The 
second pKa of phosphonate (7.49) is significantly higher than for phosphate (6.31) 
indicating that phosphate will be dianionic in biological pH, while phosphonate will be 
mono-ionized. This has driven efforts to develop phosphonate analogs with lower pKa 
such as α-fluorophosphonate or bromophosphonate (Elliott et al., 2012), (Tulsi, et al., 
2010). The C-Br bond length (1.93 Å) is longer than C-F (1.41 Å), and an α-
bromophosphonate group (pKa2  6.52) is 10-fold more basic than an α-fluorophosphonate 
moiety (pKa2   5.6), which may offer α-bromophosphonate containing ligands some 
advantage over α-fluorophosphonate ones. The synthesis and biological activity of α-
bromophosphonates has been reviewed and discussed by Downey and Cairo recently 
(Downey and Cairo, 2014). 
Table 2. ATP analogs 11-16 bearing terminal phosphate isosteres and their 
respective pKa values. Adapted from Elliott et al., 2012 
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Compd X pKa 
11 O 7.1 
12 CH2 8.4 
13 NH 7.7 
14 CHF 7.4 
15 CF2 6.7 
16 CCl2 7.0 
Carboxylic acid 
One of the most commonly used non-phosphorus isostere of phosphate is the carboxyl 
group (Ballatore, et al., 2013), (Sirivolu et al., 2012). Furthermore, carboxyl groups are 
widely represented in drug molecules with about 450 carboxyl-containing drugs marketed 
worldwide (Ballatore et al., 2013). Nevertheless, the presence of carboxyl groups also 
leads to potential drawbacks, including low metabolic stability, toxicity, and a difficult 
passive diffusion across cell membranes, particularly in the context of central nervous 
system (CNS) drug discovery (Pajouhesh and Lenz, 2005). 
Carboxylic acids have pKa that ranges from 0.5 to 4.2 depending on substituents 
(Jinhua, et al., 2006) and in the ionized form they contain two hydrogen bond accepting 
groups. For example, changing a phosphate to a carboxyl in the design of sphingosine-1-
phosphate (S1P) receptor antagonist led to an active compound 18 with 19 nM activity, to 
be compared to ~1 nM for the parent endogenous ligand 17 (Fig. 4) (Högenauer, et al., 
2010). 
 
Figure 4  S1P receptor antagonists. Adapted from Högenauer et al. 2010. 
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Sulfur-containing isosteres 
In terms of pKa and tetrahedral shape, phosphate can be bioisosterically replaced by 
sulfate and sulfonate. Sulfate and sulfonate have pKa in the range -3.4 to -1.9 and are thus 
fully ionized at physiological pH. At the S1P receptor, changing phosphate to 
sulfonylhydantoin-containing compound 19 (Fig. 4) led to a compound with an activity of 
460 nM (parent compound 17, ~1 nM). Another example is reported by Hussain et al. for 
the protein-tyrosine phosphatase 1B. While the parent inhibitor has an IC50 of 8 nM 
(compound 20, Fig.5, containing difluoromethylenephosphonic acid), the replacement of 
difluoromethylenephosphonic acid with difluoromethylenesulfonic acid gives rise to 
compound 21, which is about 1000-fold less potent (IC50 = 13 μM) (Hussain et al., 2008). 
 
Figure 5 Representative protein tyrosine phosphatase 1B inhibitor structures. Adapted from 
Hussain, Ahmed et al., 2008. 
 
Other sulfur-containing replacements are methyl sulfamate, for which pKa is 15.9 and 
acylsulfonamide with a calculated pKa of 2.5 (He, et al., 2006). Sulfamate therefore is 
likely to be a neutral phosphate isostere. 
Boronic acids isosteres 
Boron containing compounds are attractive for drug development (Bross et al., 2004), 
(Shapiro, 2009). Boron containing phosphate isosteres are boronic acids, benzoxaboroles 
and boranophosphates (Fig. 6). The pKa of boronic acids is 8.8, while that of 
benzoxaboroles is between 7.34 and 8.32 depending on the structure of the substituent in 
the 3-position (Table 2). Comparing to simple aryl boronic acids, such as phenylboronic 
acids, benzoxaboroles are more hydrolytically stable (Snyder, et al., 1958), 
Boranophosphate is more hydrophobic but still water soluble (for a review see (Elliott et 
al., 2012)). 
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Figure 6 Structures of boronic acids, benzoxaboroles and boranophosphates 
 
Table 2 pKa of Benzoxaboroles Adapted from Tomsho et al., 2011 
 
 
 
 
compd 3-position pKa 
benzoxaborole −CH2− 7.34 ± 0.02 
benzoxaborin −CH2−CH2− 8.40 ± 0.03 
3,3-gem-dimethyl −C(CH3)2− 8.32 ± 0.03 
Squaramide-based isosteres 
 
Figure 7 The pKa value of squaric acid and squaramide. Adapted from Elliott et al., 
2012. 
 
The squaramide moiety has also been studied as a phosphate isostere. Squaramide is 
prepared from squaric acid, which has pKa1 of 0.54 and pKa2 of 3.58 (see Fig. 7), suitable 
feature for phosphate bioisostery. Like phosphate, the two secondary amines of 
squaramide can indeed coordinate divalent metal ions, such as Mg
2+
. An example is found 
with the mannosyltransferase dolichol-phosphate mannose synthase; it is an Mg
2+
-
dependent enzyme with a GDP-mannose binding site. In a study by Niewiadomski et al. 
(Niewiadomski et al., 2010), the squaramide core was used to replace the diphosphate of 
GDP to give rise to eight GDP analogs. Regrettably, all synthesized compounds and 
guanosine showed only low or moderate inhibition, even for the most potent one the 2-
carboxypropylamino replacement having 64.0% of inhibition residual. (Compound 29, 
Table 3) 
Table 3 Biological activity of squarylamides and reference compounds. Adapted from 
Niewiadomski et al., 2010. 
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Compoun
d 
R 
Residual dolichol-
phosphate mannose synthase 
activity (%) 
ED50/mM 
GDP - 8.5 1.8 nd* 
Guanosine - 97.4 4.5 nd 
22 ethoxy 87.1 0.2 1.1 0.2 
23 n-butylamino 81.3 0.3 1.0 0.1 
24 nitrobenzylamino 78.0 2.0 0.73 0.2 
25 2-nitrobenzylamino 84.1 5.2 >1.5 
26 3-nitrobenzylamino 69.6 2.1 >low solubility 
27 4-nitrobenzylamino 65.1 3.0 >low solubility 
28 carboxypropylamino 91.9 5.6 0.99 0.2 
29 2-carboxypropylamino 64.0 1.0 1.0 0.2 
* Not determined. ED50: The dose of a drug that is pharmacologically effective for 50% of the population exposed to the 
drug. 
Other acidic replacements of phosphate 
Many isosteres of carboxyl group have also been shown to work well as phosphate 
isosteres because of the high similarity in the properties to phosphate. A typical example 
of carboxyl/phosphate isostere is 1H-tetrazole (Malik et al., 2014). The pKa of 1H-
tetrazole is 4.90, while acetic acid has a pKa value of 4.76. Allen et al showed that the 
carboxyl/tetrazole and carbonate/tetrazolate pairs exhibit very similar H-bonding 
environment and H-bond attractive energies are also highly similar (Allen et al., 2012). 
The relative bigger volume of tetrazole may lead however to slightly different receptor 
interactions (Fig. 8). Different synthetic methods and biological importance of tetrazoles 
have been reviewed recently (Malik et al., 2014). 
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Figure 8 Superimpositions of the ligand binding sites for the tetrazolate/carboxylate ligand 
pairs, the two pairs of ligands are as follows (tetrazole and carboxylate ligand 
codes and PDB structure code(s) in parentheses) (A) VRX in 2HWI (B) VXR in 
2I1R bound to hepatitis C NS5B polymerase and (C) 527 in 2QBP (D) 902 in 
2NT7 bound to tyrosine phosphatase 1B. Adapted from Allen et al., 2012. 
 
There are several less common examples of carboxyl/phosphate replacements that 
have been reported. For example, five-membered heterocycles such as furazan-3-ol, 
compound 30 (Fig.9), showed comparable Ki value to the endogenous ligand glutamate to 
ionotropic glutamate receptors 2, but more acidic in term of pKa2 (Lolli et al., 2006), (Lolli 
et al., 2010). 
 
Figure 9 Ionotropic glutamate receptors 2 inhibitors. Adapted from Lolli et al., 2010. 
 
There are several less common examples of carboxyl/phosphate replacements that 
have been reported. For example, five-membered heterocycles such as furazan-3-ol, 
compound 30 (Fig. 9), showed comparable Ki value to the endogenous ligand glutamate to 
ionotropic glutamate receptors 2, but more acidic in term of pKa2 (Lolli et al., 2006), (Lolli 
et al., 2010). 
Another example is substitution by 2,6-difluorophenol that has a pKa of 7.1. 2,6-
Difluorophenol was used to develop lipophilic γ-aminobutyric acid (GABA) 
aminotransferase inhibitors. (Fig. 10, compounds 31 and 32) (Qiu, et al., 1999). The 
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carboxyl group was also shown to be exchangeable by amide and hydroxamate groups at 
the GABAc receptor (Locock et al., 2013) and KCNK potassium channels (Bagriantsev et 
al., 2013). 
 
Figure 10 γ-aminobutyric aminotransferase inhibitors. Adapted from ref Qiu et al., 1999. 
2.2.3 Scaffold hopping 
Another method in lead optimization, twin of bioisosteric replacement, is scaffold hopping 
(Langdon, et al., 2010). Scaffold hopping assumes that the same biological activity can be 
achieved by maintaining some essential features in otherwise structurally different 
molecules. In scaffold hopping the core structure of the molecule is replaced with another 
scaffold that retains or improves a set of properties. The main categories of scaffold 
hopping are heterocycle replacements, ring opening or closure, and peptidomimetics (for 
review see (Sun, et al., 2012)). 
2.2.3.1 Heterocyclic replacements 
Heterocycles are ring structures where one or more carbon atoms of the parent carbocycles 
are replaced with more electronegative atoms such as oxygen, nitrogen and sulfur. For 
example, the biarylheterocyclic cyclooxygenases 2 (COX-2) selective inhibitors (Flower, 
et al., 2003), (Liedtke et al., 2012) presented in Figure 11 are different from each other 
mainly in the backbone heterocyclic rings, but their activity levels against COX-2 are 
comparable (DeWitt, 1999). 
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Figure 11 Biarylheterocyclic scaffold hopping in cyclooxygenase 2 inhibitors. 
 
Their pharmacology is however different (see for review FitzGerald et al., 2001) 
(FitzGerald and Patrono, 2001). The first inhibitor Dup 679 (Gans et al., 1990) failed to 
reach the market. Modifications based on Dup 679 led to the inhibitor rofecoxib, which 
marketed, but withdrawn due to increase in the risk of cardiovascular events. Further trial 
led to celecoxib that is still in use to treat patients with rheumatism and osteoarthritis. 
2.2.3.2 Ring closure and opening 
Ring system commonly exists in drug-like molecules, so novel scaffolds can be created 
through ring closure strategy. Intuitively, ring closure will decrease the flexibility of the 
molecule, whose binding becomes entropically less favorable for ligand binding to target. 
It is on the other hand easier for conformationally restrained molecules to penetrate 
membranes (Goetz et al., 2014), (Vieth et al., 2004). An example of macrocyclization is 
provided by the angiotensin IV peptide (Fig. 12), giving rise to the more potent 
compounds 33 and 34 to insulin-regulated aminopeptidase (Andersson et al., 2011). 
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Figure 12 Insulin-regulated aminopeptidase inhibitors. Adapted from Andersson et al. 2011. 
 
Among ring closure ideas, non-covalent ring structure closing through intramolecular 
hydrogen bonds is widely exerted and observed. When a donor and an acceptor are on the 
same molecule close enough, a dynamic equilibrium may exist between intramolecular 
hydrogen bond conformations that may facilitate the crossing of membranes, and open 
conformations in which the polar groups expose to solvent or approach to binding site. 
Intramolecular hydrogen bonding within ring systems has been studied by Kuhn et al. 
(Kuhn, et al., 2010) An example of selective neuronal nitric oxide synthase inhibitors 
bearing intramolecular hydrogen bonds is presented in Figure 13, (Labby et al., 2012) (see 
also PDB code: 3TYM). 
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Figure 13 Chemical structures of (S,S)-35-38. The putative intramolecular hydrogen bond is 
dashed. The hydroxyl of 37 may show different conformations, in which it acts 
either as a hydrogen bond acceptor or a donor, sharing the H+ in case it is 
hydrogen bond donor. Adapted from Labby et al., 2010. 
2.2.3.3 Peptide mimetics 
Structural replacement of the peptide bond has been widely studied, since peptide bonds 
may be readily hydrolyzed by protease once they are orally administrated. Peptide-
containing molecules requires alternative routes of administration such as arterial injection 
or complicated drug delivery system, for instance porous silicon nanoparticles to transport 
drug to target organs (Liu et al., 2013). Alternatively, medicinal chemists prefer to use 
structural modifications, including the cyclization of polypeptides discussed in the 
previous section (Fanelli et al., 2014). Cyclic peptides have favorable properties, such as 
increased resistance to proteolysis, specificity and constrained conformations relative to 
linear ones (Menegatti et al., 2013), and they are therefore promising candidates for 
synthetic affinity ligands (Wels et al., 2005). Multiple novel strategies for cyclization, 
such as metal-ion-assisted, sulfur-mediated cyclizations, ring-contraction involving 
lactones, azide-alkyne cycloadditions and ring-closing metathesis have been applied 
(White and Yudin, 2011). Replacement of an amide group with an isosteric cyclic group 
has also been widely used, since compounds with multiple heterocycles are able to mimic 
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the orientation and disposition of key residues at protein interfaces (Lao et al., 2014). 
Advances in the synthesis of conformational restricted building blocks and peptide bond 
isosteres have been reviewed (Vagner, et al., 2008). 
 
Small molecule mimetics of protein structures have also been designed (see a review of 
Ross et al. (Ross, et al., 2010). Protein-protein interactions and protein-peptide 
interactions are regulated by highly ordered secondary structure motifs, such as α-helices, 
β- and γ-turns, and β-sheets, so small molecule mimetics of proteins try to mimic these 
structures. Floris et al. have reviewed computational methods to design novel 
peptidomimetics (Floris and Moro, 2012). In addition, peptoids, β-peptides and stapled 
peptides are commonly used to alter the peptide properties. Peptoids are a class of 
peptidomimetics that have side chains linked directly to the peptide backbone nitrogen 
atoms rather than to the α-carbon, as they usually are in amino acids. 
2.2.4 Other considerations 
2.2.4.1 Isosteric replacements are target-dependent 
An important consideration about bioisosteric replacements is that while they prove 
effective in one circumstance they do not guarantee the success in another setting-up 
(Meanwell, 2011). For example, one very successful application of carboxyl and tetrazole 
bioisosteric interchange is for the angiotensin II receptor antagonist losartan (40) (Carini et 
al., 1991). The tetrazole moiety in losartan offers 10-fold increase in potency compared to 
the carboxylic acid analog 39. However, in a similar replacement used to develop 
cPLAA2α inhibitors, the novel tetrazole-containing analog 42 is 31-fold less active than 
the previously reported 41 (Hess, et al., 2007). 
 
Similarly, isosteric surrogates may lead to different pharmacological effects. The ester 
group containing procaine (43) is a local anesthetic drug, while replacement of the ester 
moiety with an amide group gives rise to procainamide (44), which is an antiarrhythmic 
agent. In another example, compound 46 was synthesized such that the amide bond 
replaces the ester bond in bevirimat (45), consequently leading to a significantly decreased 
antiviral activity of 46 against HIV-1IIIB (Qian et al., 2009). 
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Hypothetically, structural replacements should make almost identical interactions if 
possible. However, given the concept of induced-fit in molecular recognition as well as 
the presence of other components such as water and metal ions, “bioisosteric pairs” do not 
necessarily take the exact same position in the binding site. The problem that specific 
bioisosteric replacements are prior to others for a given target family has been discussed 
by Wassermann and Bajorath (Wassermann and Bajorath, 2011). 
 
Figure 14 Structures compiled from Hess et al. 2009 and Wassermann, et al. 2011. 
2.2.4.2 Prodrugs to deliver isosteres 
In some cases, polarity may hamper the permeability of molecules while it is necessary for 
activity. The prodrug approach can address the problem (Biot et al., 2003). For example, 
the in vitro and in vivo result difference of naphthoquinone carboxylic acid (Fig. 15) 
against Plasmodium falciparum led to a hypothesis that the penetration due to the presence 
of a carboxyl group is the key (Davioud-Charvet et al., 2001). Consequently, the ester and 
amide-masked compounds 48 and 49 were prepared and both showed improved activity. 
Replacement of the carboxyl function by a tetrazolyl group increases compound 
bioavailability, but tetrazoles may also need to be protected to facilitate the molecules 
across the membranes. For example, the cyanoethyl-protected tetrazole 50 is more potent 
than the parent compound with a free tetrazole moiety (Biot and Bauer, 2004). 
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Figure 15 Prodrugs of the naphtoquinone carboxylic acid derivative 47 protected as ester 
(48) or amide (49), and 50 with the 1H-tetrazolyl moiety protected with a 
cyanoethyl group. 
2.3 Molecular similarity in a chemoinformatics perspective 
Computational modeling has gained a major importance to the drug discovery process in 
the last fifty years. The techniques used are divided into structure-based methods that take 
advantage of a three-dimensional structure to design or screen for small molecules, and 
ligand-based methods that aim at retrieving analogs and predict the activity of unknown 
compounds (QSAR modeling). 
2.3.1 Databases to study isosteric replacement 
Databases storing information extracted from chemical structures and their activities, or 
chemical structures in complex with a protein target, represent very important tools to 
study isosteric replacements as well as to define molecular similarity. Several databases 
have been developed. Bioisosteric data require at least one pair of compounds (analogs 
differing by one functional group) as well as activity data. An example of a commercial 
database is BIOSTER, which contains 26,000 pairs of potentially bioisosteric 
replacements (Hayward, 2012). Among the freely available databases, Swissbioisostere 
automatically reports potential bioisosteric replacements extracted as ChEMBL matched 
pairs (Wirth et al., 2013); fragments are extracted using the Hussain and Rea algorithm 
that cut single bonds not part of ring systems nor resonant functional groups such as amide 
or carboxylic acids.  
 
The second type of databases contains statistics/information about molecular contacts but 
does not use biological activities. sc-PDB-Frag fragments protein-bound ligands and 
computes the interaction of each fragment with their protein environment, then sorts these 
protein-ligand interaction patterns similarly to the reference protein-ligand complex 
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(Desaphy and Rognan, 2014). Derived from both CSD and PDB, the commercial database 
IsoStar contains information of molecular interactions. This information on the 
frequencies and directionalities of intermolecular contacts is valuable to medicinal 
chemists interested in identifying bioisosteric replacements (Bruno et al., 1997).  
 
Another class of prediction of bioisosteres is based on chemical similarity alone. 
pepMMsMIMIC, a web-oriented peptidomimetic virtual screening tool, suggests which 
chemical structures are able to mimic the protein-protein recognition of the input peptide 
using pharmacophore and shape similarity techniques encoded into fingerprints (Floris et 
al., 2011). ROCS is also a shape comparison application for virtual screening based on the 
idea that molecules have similar shape if their volumes overlay well (Hawkins, et al., 
2007). Ring systems characterized by size, shape, pharmacophore features and ADME 
descriptor similarity can also be used for bioisosteric design and scaffold hopping (Ertl, 
2012). 
2.3.2 Ligand-based drug discovery: analog search and QSAR 
2.3.2.1 Representing molecules to measure their similarity 
Unlike chemical structure searches, structural similarity searches look for chemical 
structures that are related with the query molecule, not to exact matches. Researchers can 
decide the similarity degree which the hit molecules should retain. This threshold can be 
conveniently changed according to search and biological test results. Depending on 
whether the molecule is represented in 2D or 3D, 2D and 3D descriptors can be used to 
evaluate the molecular similarity. Given the relative degree of importance of the 
descriptors to similarity assessment, weighting schemes can be assigned. Most of 2D 
descriptors, such fingerprints based on graph information are easy to retrieve, allowing 
fast and efficient large scale calculations. 
 
Computationally, chemical similarity can be measured in terms of several perspectives 
depending on the molecular representation used:  
1) Topological similarity (molecule represented as a graph) 
2) Numerical descriptor-based (vector of numbers)  
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3) Fingerprint-based (bitstring) 
4) Pharmacophoric (small set of key features and distances) 
5) Field-based (grid/array typically storing information about shape and electrostatic) 
2.3.2.2 Adjacency/connectivity matrices and graph-based representation 
Molecules are composed of connected atoms through covalent bonds. Atoms are 
characterized by their types (C, O, N, etc) as well as their hybridization states (C.sp2, 
C.sp3 etc). Bonds between atoms are characterized by different bond order, for example 1 
for a single bond, 2 for a double bond and 1.5 for bonds in conjugated benzene. A simple 
way to represent molecules is through an adjacency or connectivity matrix, as for example 
in Figure 16. 
 
Figure 16 Adjacency and connectivity matrices for acetic acid. Rows and columns 
correspond to the atom numbering given on the left. Off-diagonal elements of both 
matrices represent order of the bonds between atoms pointed by row and column. 
The diagonal of the connectivity matrix represents the atomic number. Adapted 
from http://ccl.net/chemistry/resources/overview/index.shtml (accessed 2.11.2014). 
 
Chemoinformatics often use instead of these matrix graph representations. Typical tasks 
solved through graph isomorphisms are substructure search, for example using the Ullman 
algorithm (Ullmann, 1976) to identify the maximum common substructure, which is 
related to the extent of similarity in the compound topology (Stumpfe, et al., 2014). 
Another algorithm is the matched molecular pairs algorithm (Leach and Jones, 2006), 
(Cumming et al., 2013), which commonly used to find analogs differing by a single 
substitution and by this mean study chemical similarity (Kramer and Fuchs, 2014). 
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2.3.2.3 Numerical molecular descriptors 
Descriptors are numerical values that describe the molecules. Usually 1D descriptors, for 
example the molecular mass, are properties of the structure; 2D descriptors are obtained 
from the 2D structure; 3D are obtained from 3D structure (some values may then be 
conformation-dependent). VolSurf, Dragon and JOELib are typical softwares for 
numerical descriptors calculation. VolSurf compresses the information present in 3D maps 
into few 2D descriptors for optimization of pharmacokinetic properties (Cruciani et al., 
2000), Dragon 6 can calculate up to 4885 molecular descriptors and JOELib contains two 
main types: native value and atom property descriptors. 
 
The application of descriptors is to visualize the chemical space for example using data 
transformations such as principal component analysis, multidimensional scaling or a 
neural network self-organizing map, as well as other clustering methods. The key idea is 
that molecules with similar descriptors will locate nearby. 
 
Another application of numerical molecular descriptors is QSAR modeling: a statistical 
model relating a set of stimuli variables (X) to the potency of the response variable (Y). 
QSAR is derived by finding a relationship between chemical structures and biological 
activity in training data-set. Descriptors thought suitable to describe the relationship are 
selected and then some form of statistical analysis is performed to generate a model, 
which is validated with a test data set. Unlike physical methods, such as molecular 
dynamics, empirical QSAR methods do not rely on any understanding of the physics. 
 
Though QSAR model is a powerful tool for drug discovery (Golbraikh et al., 2014), a lot 
caution should be taken in order to avoid misuses and misunderstandings of this technique 
(Doweyko, 2008). First off all, erroneous association of correlation with causation should 
be figured out. Validation is a crucial aspect of any QSAR modeling. Often, a high value 
of leave-one-out cross-validated R
2
 (LOO q
2
 > 0.5) is considered as a proof of the high 
predictive ability of the model. However, some studies show that a high LOO q
2
 value do 
not necessarily indicate a predictive model and external validation is the only way to 
guarantee reliable QSAR models (Golbraikh and Tropsha, 2002). 
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2.3.2.4 Molecular fingerprints 
Molecular fingerprints are a specific type of molecular descriptor that encodes molecules 
into bitstrings. Molecules are split into fragments and presence/absence is recorded as 1/0. 
UNITY 2D and fragment-based Daylight fingerprint are well-known examples. There are 
two types of fingerprints which the Daylight system provides. One is the “difference” 
fingerprint, which is used for the bond changes which occur during a reaction. Another is 
the “normal” structural fingerprint, which is useful as a superstructure search screen. If a 
query molecule is a substructure of a target molecule, then all of the bits set in the query 
molecule will also be set in the target molecule. 
 
Figure 17 Molecular split and comparison with reference. 
 
Fingerprint of molecule above:                       1 0 0 1 0 1 1 0 0 1 0 
Fingerprint of a query molecule (not shown): 1 0 1 0 1 0 1 0 1 1 0 
 
The fingerprints for two molecules can be used to calculate structural similarity using the 
Tanimoto coefficient (or Jaccard coefficient). Tanimoto coefficient is commonly used to 
investigate structure similarity of compounds. T (a, b) of molecules A and B is defined by: 
         
  
         
 
In this equation, N represents the number of attributes in each object (a, b), c in this case is 
the intersection set. 
 
For Daylight fingerprints, two structures are considered dissimilar if T   0.85. 
Therefore,           
 
       
       
Fingerprints are often used as a pre-screening tool in a substructure search to avoid 
running unnecessarily a graph isomorphism algorithm. 
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2.3.2.5 Shape and electrostatics 
It is commonly recognized that shape and hydrogen-bonding capability are among the best 
description of a molecule that is independent from chemical structure if we want to 
understand molecular recognition properties (Böhm et al., 2004). Among commonly used 
tools, ShaEP superimposes molecules based on shape and electrostatic potential (Vainio, et 
al., 2009). BRUTUS is another rigid-body molecular superposition and similarity 
searching program based on grid algorithm, which also considers properties from charge 
distributions and van der Waals shapes of the compounds (Rökkö et al., 2006). All these 
methods are essentially used for ligand-based screening through shape-based comparison. 
2.3.2.6 Pharmacophoric representation 
Pharmacophore is an old concept, which describes molecular features important for 
activity. These features include hydrogen bonding or accepting groups, hydrophobic or 
ionic centers, the distances that relate them and geometry in 3D space. Pharmacophoric 
representations can be used to compare molecules and they are mainly used as filters to 
query databases. An example of a pharmacophore search for protein-protein interaction is 
presented in Fig. 18. (Zhang, unpublished results) 
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Figure 18 An example of protein-protein interaction pharmacophore; Center, yellow lines in 
Yellow: aromatic (Ar), hydrophobic (Hy); Red: excluded volumes and hydrogen 
bond acceptors (HA), negatively charged groups (NC); Blue: hydrogen bond 
donors (HD), positively charged groups (PC) 
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3 Aims of the study 
The major aims of this study were to investigate small molecule mimics of phosphate 
groups, using both computational and synthetic approaches. 
 
The specific research aims were as follows: 
1. to construct a workflow useful to mine the Protein Data Bank for local 
structural replacements, 
2. to identify previously unrecognized local structural replacements that could be 
useful bioisosteres of phosphate, 
3. to uncover the local structural replacements of a ribose linker (3'-5' connected), 
4. to characterize the structural mechanisms in the recognition of local structural 
replacements (bioisosteres), 
5. to probe the human macrodomain protein 1 (MDO1) binding site with 
potentially bioisosteric replacements of the phosphate groups as well as distal 
ribose of ADPribose including ligand-based design, synthesis, and retrospective 
docking analysis, and  
6. to discover compounds binding to MDO1 using a virtual screening approach. 
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4 Materials and Methods 
4.1 Computational section 
4.1.1 Material 
 Protein Data Bank (PDB) 
Since 1971, 98% of all structures of proteins or their complexes, mainly consisting of X-
ray crystallography (88.6%) and NMR (9.4%) data have been stored in the PDB. One 
typical PDB format file contains atomic information of macromolecules, ligands, water 
and ions. The main content of PDB files is stored in the ATOM or HETATM rows. By 
tradition, ATOM is initial flag of macromolecules, such as proteins and nucleic acids, 
while HETATM remarks small molecules. Detailed information is then included, such as 
atom number, atom name, residue name, chain identifier, residue sequence number, atomic 
Cartesian coordinates, occupancy and temperature factor. 
 
 
 The resolution filter 
 
In X-ray crystallography, resolution is a measure of the quality of the fit of the modeled 
3D structure with the electron density data. Ideally, X-rays are scattered identically if all 
protein molecules in a crystal are aligned in the same way. In reality, anisotropy of protein 
alignment in the crystal, several possible low energy conformations, and local flexibility 
results in a diffraction pattern that does not reflect the ideal case. The main difference of 
higher and low resolution is usually seen on surface loops and in long side chains (Arg, 
Lys, Glu, Gln) for which rotamers are might not be correctly modelled. The majority of 
the structures (93.6%) are within four ranges of resolution: 1-1.5 Å (9.0%), 1.5-2 Å 
(38.1%), 2-2.5 Å (30.6%), and 2.5-3 Å (15.9%). Hydrogen atoms are not seen unless for 
the highest quality structures with resolution of 1 Å or under (Fig.19A). With resolution of 
3 Å or lower (Fig.19D), we can only see the contours of protein chain while the position 
of side chain is less accurate. In our study, we used 2.8 Å as a resolution filter. We suppose 
this criterion is suitable to allow us obtain enough relevant data. The data is meant to be 
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analyzed by chemists, who themselves can exert caution when knowing that a given 
example is of relatively low resolution. 
 
 
Figure 19 Electron density maps for structures with a range of resolutions are shown. The first three 
show tyrosine 103 from myoglobin, from entries 1A6M (1.0 Å resolution), 106M (2.0 Å 
resolution), and 108M (2.7 Å resolution). The final example shows tyrosine 130 from 
hemoglobin (chain B), from entry 1S0H (3.0 Å resolution). In the pictures, the blue and 
yellow contours surround regions of high electron density, and the atomic model is shown 
with sticks. Reproduced with permission of the PDB. (Berman, 2000) 
4.1.2 Methods 
 Data mining 
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In this work, a computational automated workflow written in Python language was 
built (Fig.20).  
 
Figure 20 Flow chart of data mining. 
The workflow is applied to extract the local structural replacements (LSR) that occupy 
the positions of the individual ,  and  phosphates or ribose moieties in POP, AMP, 
ADP and ATP-binding proteins. The workflow can be parameterized by many aspects and 
the individual parameters used for the run presented are given at the end of this section.  
 
Technically, the workflow uses and connects different external tools: (1) Blastp for 
sequence-based retrieval of protein homologs (Johnson et al., 2008), (2) TM-align for 
protein structure superimposition (Zhang and Skolnick, 2005), (3) ShaEP for assessing a 
score for the ligand-based superimposition of molecular fragments (Vainio et al., 2009), (4) 
Babel to convert extracted 3D structure files to SMILES code (O’Boyle et al., 2011), (5) 
Needle from the Emboss package to conduct global sequence alignment (Rice, et al., 
2000). Setting up the workflow required developing extra lines of code for example the 
connectivity needed to be rewritten in order to run ShaEP properly and manage missing or 
incorrect connectivity in PDB files. For the purpose of visualization and data analysis, 
other python tools have been used, for example a tool that implemented the Kabsch 
algorithm to superimpose small molecule fragments (Borrel et al., unpublished). The 
software R was used for all statistical analysis and presentation of data.  
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At the first step, the workflow retrieve from PDB (Berman, 2000) the three-
dimensional structures of proteins that are homologous to proteins with a bound POP, 
AMP, ADP, and ATP (named “reference ligands”; reference ligands are each bound to 
several “reference proteins”). Protein chains are often problematic for automated 
extraction protocols and a single reference ligand is taken for any reference PDB files. 
Proximity (at least one atom within 4.5 Å) is used to select the protein chain(s) of interest, 
and a global sequence alignment used to eliminate redundancy in the protein chains of a 
given PDB file. The protein chain(s) considered are (is) appended to the PDB file name in 
the output of the workflow. 
 
Secondly, for each reference protein found in the previous step, the workflow retrieve 
and superimpose homologues and keep those with a non-nucleotide ligand bound at 
equivalent position to the reference ligand (these homologs are referred to as LSR-
containing ligand and LSR-containing protein). Chains of the LSR-containing proteins are 
identified by proximity (4.5Å) as above and appended to the file names. Metrics (RMSD, 
length of superimposed region and percent identity) are output from the whole body 
protein superimposition. In this study, only near identical proteins are considered and 
perhaps therefore no global RMSD deviation above 3.5Å was found and all 
superimposition were kept in the study (a high RMSD indicates a poor superposition that 
may be due to conformational differences such as motions upon ligand binding due to 
protein being homologues). At that stage, data on the binding site flexibility (C and all 
atoms RMSD; longest deviation) is extracted for the subset of proteins with exactly 
identical amino acid type and numbers in the reference and in the LSR-containing sets. A 
set of overrepresented ligands are automatically removed to speed up the analysis, based 
on a manually constructed list; this list is a parameter in the workflow. 
 
In the third step, LSRs are extracted at the level of individual groups; for example 
ADP is composed of three “replaceable” groups that we study here, i.e. ribose, - 
phosphate, and - phosphate. In the case of phosphate, extraction of atoms belonging to 
the LSR is based on a single sphere centred on the phosphate; and in the case of ribose 
extraction is based on several spheres centred on every atoms (O5', C5', O4 ,´ C4', O3 ,´ C3', 
O2 ,´ C2' and C1'). Target proteins with empty LSRs are removed. Redundant groups are 
then merged and some complexes filtered out when they do not conform to set criteria, for 
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example a too small overlap of the LSR on top of the considered group of the reference 
protein (-, - and - phosphate or ribose). The SMILES of the extracted local structural 
replacements are then used to sequentially assign to the “replacing” groups exclusively 
one of nine non-overlapping categories containing: phosphorus, cycle, SO2; CON 
(generally carbamoyl or amide); COO (ester or carboxylic acid); exclusively C; only C 
and O; only C and N; only C, O and N; Other.  
 
The empirically optimized filters used for the run, which is presented are as follow: 1) 
PDB August 2014 release (102158 entries); NMR entries are not considered; 2) 
resolutions are better than 2.7 Å; 3)  homologues were found by a BLAST e-value filter of 
10
-100
; 4) manually built list of  pre-filtered compounds: TTP, DCP, DGT, DTP, DUP, 
ACP, AD9, NAD, AGS, APC, AOV, UDP, GDP, GTP and CTP, in addition to AMP, 
ADP, ATP and POP (in the version of the paper submitted, ANP will be further removed); 
5) definition of the binding site as any amino acid with at least one atom within 4.5 Å of 
the bound reference ligand; sphere extraction of atoms belonging to the LSR in the case of 
phosphate with a radius of 3.0 Å; and in the case of ribose of 2.5 Å; a shape component of 
the score computed by ShaEP larger than 0.2 required. 
 
 Python scripting 
The workflow is developed in Python. Guido van Rossum created the Python in 1989. 
Python is probably the most popular programming language, and it is used not only by IT 
giant such as Google, Yahoo but NASA. Python is multi-paradigm: procedural, 
declarative, functional, and object-oriented. So far, two basic versions of Python were 
released: 2.0 on 16th October 2000, Python 3.0 on 3rd December 2008. The latest Python 
versions are 2.7.8 and 3.4.2. When this project started, I used Python 2.7.2. The 2.x and 
3.x series of Python will work for most cases, with a few minor changes, for example 
“print” is a statement in Python 2.x instead of a function in Python 3.x. 
Python has a large and comprehensive standard library. The standard library contains 
several kinds of components: data types, built-in functions and modules. Besides, there are 
several extensions such us Biopython (Cock et al., 2009) a tool for biological 
computations; Numpy (Walt, et al., 2011) providing a static array data type, which speed-
up numeric computations; Matplotlib (Hunter, 2007) 2D and 3D plotting library for 
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Python; and Scipy based on Numpy, to do scientific computing, such as statistics, 
optimization, and Fourier transforms. 
In this chemoinformatics project that was not computationally nor graphically demanding, 
the python standard library was used, while the figures were plotted with R (R 
Development Core Team, 2011). R is a software facilities suite for data manipulation, 
calculation and graphical display. 
 BlastP 
Basic local alignment search tool (Blast) was used to retrieve all the structures of a given 
(reference) protein sequence. Blastp uses a heuristic algorithm for comparing primary 
protein amino acid and DNA nucleotide sequences expressed as a string (a succession of 
letters, 20 for proteins and four for DNA). (Altschul et al., 1990) One of the most widely 
used bioinformatics program for sequence searching, a BLAST search allows comparing a 
query sequence with a sequence database, and identifies target sequences that resemble the 
query sequence above a certain threshold. BLAST use high-scoring segment pair (HSP) 
scores to characterize the match of query sequence and individual one in database. The 
significance of this match, expressed as expectation or expects value (E-value), relates to 
the number of hits of a given match score one can "expect" to see given the size of the 
database and the length of the query. The E-value decreases exponentially as match score 
increases.  
In this study, the e-value setting-up of protein-protein BLAST "blastp" the threshold for 
retrieving proteins identical to queries available in the PDB was empirically set to 1×10
-100
. 
This value should allow to recover mutants, truncated proteins (e.g. fragments not seen in 
crystallography), or proteins whose sequence contain a purification tag such as the His-tag. 
 TM-align  
TM-align is a software that identifies the optimal alignment between the tertiary structure 
of protein pairs (Zhang and Skolnick, 2005). TM-align gives the sequence identity value 
(ID) calculated over the C-alpha carbons that are used to make the alignment of structures.  
The Root Mean Squared Deviation (RMSD) of protein pairs is also provided. The RMSD 
is defined given two sets of n point of graph v and w: 
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Superimpositions of paired proteins were done by translation vector and TM-score 
rotation matrix. The matrix and vector are obtained from the coordinates of all counterpart 
atoms in paired proteins. I embedded TM-align into Python scripts to automate the 
proteins superimposition. 
  Finding reference atoms 
It was technical difficult to locate the atoms belonging to phosphate or ribose fragments to 
be used as references in the PDB file. Here, this could be done taking advantage of the 
labels in the PDB files. If not for these labels, I would have been required to use 
substructure search algorithm such as the Ullmann algorithm, (Ullmann, 1976), which is 
less straightforward than it seems because the connectivity matrix of HETAM is not found 
in PDB files.  
In a preliminary version of the workflow, the bridge oxygen of POP and ADP dataset was 
assigned as centroid of the probe sphere. For the AMP dataset, the center atom was a 
phosphorus atom. For ribose, a sphere centroid (a pseudoatom) was defined using the 
center of mass of the extracted coordinates of O4', O3' and O2' atom. Starting with the 
centroid atom coordinates obtained from a reference protein, the search was terminated if 
there were less than 3 atoms within the probe sphere with radius 3 Å. Otherwise, the 
sphere probe was expanded up to 4.5 Å. Atoms of ligands co-crystallized with 
superimposed protein within this space were extracted, defining as structural replacement 
of phosphate or ribose. 
During the analysis of the preliminary result, we thought it would be more accurate if the 
center atom was assigned to each individual phosphorus atom. This idea was also applied 
to the ATP dataset that was added in this second version. In addition, we used a shape-
based superimposition to control the relevance of the extracted fragment (software ShaEP, 
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see below). 
 ShaEP 
ShaEP, developed by the group of Mark S. Johnson from Åbo Akademi University 
(Vainio, et al., 2009), was used to produce volume- and electrostatic- overlap (shape) 
scores. ShaEP contains two main functions: a scoring function, that scores the 
superimposition of atoms represented by their electrostatic potential and local shape using 
Gaussian functions; and a genetic algorithm that finds the superimposition that maximize 
the score overlap of the molecules. In my study, only the scoring was conducted since 
further optimization may change the extracted substructure spatial characteristics from 
protein-ligand complex. 
4.1.3 Homology modeling, docking and virtual screening 
 Molecular modeling of MDO1 
A structural model of the ligand-bound conformation of human MDO1 was constructed 
based on the crystal structure of Archaeoglobus fulgidus Af1521 (PDB: 2BFQ)(Karras et 
al., 2005) using the software Swissmodeller (Biasini et al. 2014). The modeling was done 
early in the study, before the crystal structure of MDO2 became available, but this should 
not affect the conclusions since the ADPr binding site is well predicted and likely not 
influenced by the template. Before docking, the modeled human MDO1 was handled with 
protein preparation wizard (Schrödinger Ltd). The atom type, side chain protonation states, 
and hydrogen network in the protein were assigned using PROPKA at pH 7.0. Glide 
receptor grids were generated by defining a 10 Å box localized at the centroid of ADPr 
copied from the A. fulgidus macrodomain protein (PDB: 2BFQ). 
 Ligand preparation  
Two tools were used: Balloon, for the study conducted in 2010-2011; and Ligprep 
(Schrödinger Ldt), for which the license was acquired later, for the studies conducted in 
2012-2014. Balloon, free software from the Mark S. Johnson group, is enumerating low 
energy 3D conformations of molecules from a 2D format, using a genetic algorithm and a 
Pareto multi-objective evaluation (Vainio et al., 2007). The input format can be MOL2, 
SDF or SMILES. Balloon performs energy minimization using the MMFF94-like force 
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field. By default, Balloon uses distance geometry only.  
For the analysis of the binding modes of the synthesized compounds to MDO1, the 
possible ionization states of ligand candidates were generated by LigPrep Suite with 
default parameters. The global minimum energy conformation of each structure was 
identified using OPLS 2005 force field and no tautomers were generated. 
 Docking simulations  
Molecular docking, as a routinely used computational method, helps to model molecular 
recognition events more rapidly and at lower costs than X-ray crystallography (but at the 
expense of accuracy). Docking programs try to simulate the complementary relationship 
between ligand and protein in terms of volume and interaction. Molecular docking address 
three questions: 1) finding the native binding pose of individual ligands in protein binding 
site; 2) estimate the relative binding affinity of each individual ligand and 3) discriminate 
ligands from non-binders (decoys). Technically, the docking problem is divided into a 
sampling problem and a scoring problem.  
 
The sampling process should fish out experimental binding pose of ligand in binding site 
and scoring functions should give rise to highest score among all binding poses. So far, 
docking software routinely includes ligand flexibility. Allowing the flexibility of the 
protein active site, at least at the level of side chains, is possible but extremely expensive 
computationally, and leads to difficult scoring problems. Complete flexibility of the 
system or explicit inclusion of water molecules is beyond reach of most computer 
resources (Meng et al., 2011). 
 
Scoring functions are divided into three types: force-field-based, empirical and 
knowledge-based. Traditional force-field-based estimates the binding affinity by 
summarizing the non-bonded (electrostatics and van der Waals) interactions between 
sampled ligand and protein pose. Advanced force-field-based scoring functions also 
include hydrogen bond, solvation and hydrophobic contribution. Knowledge-based 
functions extract structural information from Protein Data Bank (PDB) and Cambridge 
Structural Database (CSD), and employ the Boltzmann law to transform the atom pair 
preferences into distance-dependent pairwise potentials (Shen et al., 2011). “Empirical” 
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scoring functions use a training set containing binding affinities. 
 
During the course of my thesis, I have been using four docking programs: Surflex-Dock 
(Tripos) (Chikhi, et al., 2008), Gold (Hartshorn et al., 2007), Autodock (Morris et al., 
2009), as well as Glide-SP and Glide-XP (Schrödinger) (Friesner et al., 2006). Gold was 
the main software used by the group in 2010-2012 until the Schrödinger software license 
was acquired. 
 
For the analysis of the binding modes of the synthesized compounds, to MDO1, the 
molecular docking experiments were carried out with Maestro suite Glide (Friesner et al., 
2006). Default parameters were used. Van der Waals scale factor was 1.0, and partial 
charge cutoff was 0.25. Ligands were flexibly docked into the binding groove using the 
Glide XP protocol. 
4.2 Synthetic chemistry section 
 Materials and general procedures 
All reagents were commercially available. They were acquired from Fluka (Buchs, 
Switzerland) and Sigma-Aldrich (Schnelldorf, Germany) and were used without further 
purification. All reactions in anhydrous solvents were conducted in oven-dried glassware 
under anhydrous argon. Thin-layer chromatography (TLC) was performed using Silica Gel 
60 F254 (Merck) and Silica Gel 60 NH2 F254s aluminium sheets (Merck), visualized by UV 
illumination and stained with ninhydrin in EtOH (1.5% w/v). The 
1
H and 
13
C NMR 
spectra were recorded on a Varian Mercury-VX 300 spectrometer as solutions in CDCl3,
 
DMSO-d6 and CD3OD. Chemical shifts (δ) are reported as parts per million (ppm) relative 
to the solvent peak (CDCl3 7.26 and 77.21 ppm, DMSO-d6 2.50 and 39.52 ppm, CD3OD 
3.31 and 49.00 ppm). Multiplicities of peaks are represented by s (singlet), d (doublet), t 
(triplet), q (quartet), quintet (qn), and m (multiplet). HPLC–MS analyses were performed 
to determine purity of all tested compounds. Purity of all tested compounds was > 95%. 
Mass spectra were measured on a Bruker Daltonics Esquire-HPLC spectrometer, with 
XTerra MS RP18 column (4.6 mm × 30 mm, 2.5 μm) or on a JEOL JMS-AX505 (Tokyo, 
Japan) spectrometer with direct input and electron ionization (EI). 
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4.3 Biological testing 
This section introduces experiments conducted by our collaborators. ITC, DSC and DSF 
experiments were conducted at the University of Oulu (Finland) in the group of Docent 
Lari Lehtiö. ADPribose and poly-ADPribose radiolabeled competition assay were 
conducted in the group of Dr. Päivi Tammela, University of Helsinki, Finland 
 
 Competition binding assay 
Binding assays aimed to measure interactions between two molecules, such as a protein 
binding into small molecule. Competitive binding assays were based on competition of 
unlabeled ligand (passive) against labeled one (active) during protein-ligand reaction. The 
common protocol of a competition assay was performed such that the binding site of 
receptor was saturated by radiolabeled ligand firstly, then doses of the unlabeled one were 
added and displacement of the labeled ligand measured. This experiment was repeated for 
different doses of the unlabeled ligand. IC50, the concentration of unlabeled ligand 
necessary to displace 50% of the labeled one, can then be estimated. Ki, which was 
independent of the labeled ligand binding affinity, can then be estimated from IC50 using 
for example the Cheng-Prusoff equation. 
 
Competitive assay for poly-ADP-ribose (poly-ADPr) binding. MDO1, expressed in 
Escherichia coli, was coated on yellow Delfia 96-well plates (PerkinElmer) and unbound 
protein was removed by washing after overnight incubation. Biotinylated poly-ADPr, 
produced by recombinant human PARP1 from a mixture of NAD
+
 and 6-biotin-NAD
+
, 
was added to the wells containing MDO1 and incubated for 1 h at RT on a shaker. 
Unbound poly-ADPr was removed by washing with 3 × 600 µL of 10 mM MOPS (1 mM 
NaCl, pH 7) by using a plate washer. Europium-labelled streptavidin (40 ng/mL in Delfia 
Assay Buffer) was added and after incubating at RT for 30 min, unbound streptavidin was 
removed by washing (4 × 600 µL, Delfia Wash Buffer). The plate is left to dry at RT and 
then 200 µL of Delfia Enhancement solution was added to the wells. After 5 min shaking 
at RT, time-resolved fluorescence at excitation 340 nm, emission 615 nm was measured 
with a Victor plate reader. The ability of compounds to compete with poly-ADPr binding 
to MDO1 was assessed by comparing the europium signals from treated and non-treated 
wells. 
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Competitive assay for ADP-ribose (ADPr) binding. MDO1 was coated on Scintiplates 
(PerkinElmer) as described above. 
3
H-ADPr was added and after incubation, unbound 
3
H-
ADPr was removed by washing. The plate was dried at RT and measured by Microbeta 
scintillation counter (PerkinElmer). The ability of compounds to compete with 
3
H-ADPr 
binding to MDO1 was assessed by comparing the signals from treated and non-treated 
wells. 
 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) was used to determine how much energy was 
released when protein-ligand binding takes place, providing an estimate about the enthalpy 
change (ΔH). ITC used thermocouple circuits to detect temperature differences between 
the reference cell and the sample cell with the receptor. Ligand was added into the sample 
cell, causing heat either absorption or release. The power needed to maintain balanced 
temperatures between the sample and reference cells were measured. 
 
ITC also provides a quantitative measure of the binding affinity (Kd) of a ligand to a 
protein. According to relationship            
  
  
         , Gibbs energy ΔG 
and entropy change ΔS can be then calculated. 
 
 Biological assays of MDO1 using differential scanning fluorimetry  
 
Differential scanning fluorimetry (DSF) is used to investigate to which extent ligand 
binding could stabilize the protein structure. Protein unfolding happens with a certain 
temperature range, the midpoint of the transition (defined as Tm) from protein folding to 
unfolding is different in absence and presence of ligands. Increased transition temperature 
when a compound is present indicates binding; the higher Tm implies the tighter ligand 
binding. Fluorescence-based thermal shift assay uses a dye that is fluorescent in 
hydrophobic environment but not aqueous solution to characterize the ligand binding to 
protein. Upon temperature-triggered protein unfolding, the protein hydrophobic core 
becomes exposed to the dye and triggers the fluorescence.  
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Testing protocol: The expression construct for human MDO1 (residues 58-325) with an 
N-terminal 6×His-tag and a thioredoxin fusion tag followed by a TEV cleavage site (pNH-
TrxT) was a generous gift from the Structural Genomics Consortium, Oxford. Protein was 
expressed by transforming the plasmid into Escherichia coli Rosetta2 (DE3) cells. 
Glycerol stock was used to inoculate small 5-mL pre cultures grown overnight in Luria 
broth (LB) media, which were then used to inoculate two large 1-L cultures containing 
Terrific broth (TB) auto induction media with trace elements (Formedium, UK). The 
media was additionally supplemented with 8 g/L glycerol. The cultures were allowed to 
grow up to OD600 of 1.5 at 37 °C with shaking after which the temperature was reduced to 
18 °C and the cultures were allowed to grow overnight (14-16 h). The cells were then 
collected by centrifugation (5500×g, 25 min, 4 °C), resuspended in lysis buffer (50 mM 
HEPES, pH 7.5, 500 mM NaCl, 10% glycerol, 10 mM imidazole, and 0.5 mM TCEP; 1.5 
mL/g of cells) and stored at -20 °C. 
The cell suspension was thawed, 10 µg/mL DNAase, 0.1 mM Pefabloc, and 0.25 mg 
lysozyme was added followed by incubation on ice for 5 min. The cells were disrupted by 
sonication and the lysate was cleared by centrifugation (35000×g, 30 min, 4 °C). The 
supernatant was filtered using a 0.45 µM filter syringe before it was loaded to two 1-mL 
HisTrap HP columns (GE Healthcare, UK), which were pre-charged with Ni
2+
 and pre-
equilibrated with binding buffer (20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 10 
mM imidazole, and 0.5 mM TCEP). The bound protein was washed with 5 column 
volumes (10 mL) of buffer supplemented with 25 mM imidazole and eluted with buffer 
containing 350 mM imidazole. The eluted protein fraction was concentrated and diluted in 
size exclusion buffer (20 mM HEPES, pH 7.5, 250 mM NaCl, 5% glycerol, and 1 mM 
TCEP) to a final volume of 10 mL to bring the imidazole concentration down to 50 mM. 
TEV protease was added (1:30 molar ratio) and the sample was incubated overnight at 
4 °C. The cleaved protein was run again through a 1-mL HisTrap HP column (GE 
Healthcare, UK). The flow-through was collected and concentrated to perform size 
exclusion chromatography using Superdex S-75 column (GE Healthcare, UK). The 
collected fractions were pooled, concentrated and divided into small aliquots which were 
flash frozen in liquid nitrogen and stored at -80 °C. 
The binding of the compounds was tested using DSF. The concentration of the protein 
used was 0.25 mg/mL in a reaction volume of 30 µL. Sypro orange was used as a reporter 
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dye. The different ligands that were tested were used at a final concentration of 1 mM. All 
the conditions were performed in triplicates. MDO1 without any ligand and MDO1 with a 
1 mM AMP, ADP and ADPr were used as controls. The experiment was performed on a 
RT-PCR machine with the starting temperature of 20 °C after which the temperature was 
increased at 1 °C for every 60 seconds until the temperature reached 90 °C. The 
fluorescence readings from the environmentally sensitive Sypro orange reporter dye were 
recorded for every 1 °C increment of the temperature. Data were normalized and analyzed 
using Boltzmann sigmoidal curve fitting GraphPad Prism 5.0 (GraphPad software Inc., 
US). 
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5 Results and discussion 
For clarity, the compounds synthesized as part of the thesis work are numbered starting 
from 1. The results presented in this section follow the specific aims 1-6.  
 
In this thesis, I first computationally studied the local structural replacements of phosphate. 
These replacements are not “linked” to biological activities, but only to observation of 
molecular complexes in PDB structures. Nevertheless, these local structural replacements 
should provide medicinal chemists with new ideas for synthesis of novel compounds. 
Furthermore, many of the compounds shown as examples have nanomolar or micromolar 
activities, which suggest that these replacements are favorably binding to the protein. As a 
result, we recognized recurring mechanisms that will enrich our understanding of the 
molecular recognition of phosphate groups. I then designed two series of ADPr analogs 
that contained replacements of the phosphate groups, and synthesized, purified and 
analyzed them. Five active compounds were found to bind to the MDO1 protein when 
tested using DSF. The virtual screening results will be presented at the end of this section. 
 
The most critical concepts in this thesis are those of local structural replacements and of 
bioisosteres. These concepts are overlapping but not identical. 
 
 Bioisosteres emphasize similarity in chemical properties – isosteres – as well as in 
biological activities, i.e. similar binding affinities. Nonetheless, biologically active 
compounds with bioisosteric replacements may be the result of completely or 
partially different modes of binding. 
 
 Local structural replacements, on the other hand, contain the idea that the 
fragments studied occupy the same location in the binding site. Nonetheless, 
biological activity (binding affinities) may vary greatly. Furthermore, the binding 
affinity depends on the chemical structure of the complete ligand, not only the 
local structural replacement considered. Molecular interactions may or may not be 
conserved when local structural replacements are used, as will be presented in this 
thesis. None of the local structural replacement presented here is “new” in the 
chemical sense – all have been synthesized and crystallized in order to be found in 
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the PDB. Therefore, it is the comparison with a reference protein and the recurring 
aspect (i.e. the same replacement is found several times) that makes them novel or 
interesting. 
5.1 Workflow to mine the Protein Data Bank for local structural 
replacements 
 Data collection 
A summary of the data extracted at each step of the workflow is presented in Table 4.  
Table 4. Number of LSR-containing complexes and ligands collected in each of the four 
datasets 
 
 Reference 
complexes 
in PDB 
Reference 
complexes 
filter 
LSR-containing 
+ empty 
LSR-
containing 
complexes 
(empty 
eliminated) 
Unique 
LSR-
containing 
ligands 
After ShaEP filter 
Total with BS 
identical 
to BS 
reference 
Ribose 
 
 
α-P β-P γ-P 
AMP 430 116 1181 358 576 409 227 205 - - 
ADP 1372 314 3576 1390 1050 703 572 523 400 - 
ATP 814 271 3067 1048 1006 730 461 407 318 239 
POP 202 42 286 118 240 121 - 51 59 - 
 
We constructed a total of four sets of 116, 314, 271, and 42 unique proteins that are in 
complex with pyrophosphate (POP), AMP, ADP, or ATP. Each of these reference proteins 
is also crystallized in complex with at least one LSR-containing ligand. The workflow is 
automated and in the run presented, criteria were empirically selected for optimal 
parameters that avoid depleting the dataset from otherwise interesting examples while 
leaving decision as to whether complexes are interesting to the end-user. The LSR-
containing proteins are first selected using a resolution filter of 2.7 Å, and a criteria of 10
-
100
 expect value to the Blastp search. This second criteria was chosen so that it “let through” 
very related proteins, which may come at valuable examples. These may be closely related 
species or proteins that have been mutated or engineered (at the binding site or elsewhere, 
for example by addition of a His-tag for purification). The selected proteins are in ~30% 
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(2914/8468) of the cases entirely identical at the binding site (same of amino acids, same 
numbering) (Table 4). 
 
The LSR-containing proteins were superimposed on top of their respective references 
(Figure 21). As a result, the superimposition appears very reliable, which is not surprising 
considering that identical or near identical structures are at hand. During the rather 
exhaustive manual analysis of the data, we did not find local structural replacements that 
were offset as a result of erroneous or ambiguous whole-protein superimposition; even 
when conformational changes did take place they were limited to a restricted region of the 
binding site.  
 
Figure 21 Distribution of for protein superimposition (A-D), RMSD of completely identified 
protein with reference (Å); (E-H), all target protein RMSD (Å). RMSD are for the 
datasets (A, E) POP; (B, F) AMP; (C, G) ADP and (D, H) ATP datasets. 
 
In total and after elimination of redundancy and empty binding sites, 929 unique LSR-
containing ligands were found, that when taking together their diverse occurrences they 
account for 3462 local structural replacements. The most represented LSR-containing 
ligands are adenosine derivatives (PDB ligand code ANP, 2267 occurrences; 3P1, 151; 
IMP, 115), kinases inhibitors (STU, 183; L20, 123; R68, 91; R69, 99; VX6, 83), HSP90 
inhibitors (3FD, 147; GDM, 143), and crystallization agents bound at the nucleotide site 
(BET, 149; SEP, 99). 
 
 Reference groups 
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The 116, 314, 271 and 42 sets of reference proteins represent a variety of folds. Kinases 
proteins account for a majority of the reference proteins: kinase 28% (205 out of 743), 
HSP 5% (34) and others 68% (504). It is not surprising given the large size of the kinome 
and their key role as anticancer drug targets. The other proteins under study are Heat 
Shock proteins, proteins active on DNA and RNA such as ligase and synthases, and 
proteins involved in metabolic reactions, as well as myosin.  
 
All these proteins are bound to nucleotides, which presumably represent their natural 
endogenous ligands. The terminal -, - and -phosphates of respectively AMP, ADP and 
ATP, as well as both phosphates of POP, contains three oxygen atoms not bonded to heavy 
atoms: two hydroxyl groups that may play roles as hydrogen bond donor/acceptors, and a 
carbonyl group that may be a single hydrogen bond acceptor. Upon ionization, the 
hydroxyl groups act as a hydrogen-bond acceptor and individually may carry one negative 
charge; the terminal phosphates therefore may carry up to two negative charges. 
Connected internal phosphate groups, i.e. the phosphate of ADP and both the  and 
 phosphates of ATP contain one free hydroxyl group and therefore may be singly 
negatively charged. At physiological pH, for example the AMP phosphate group is 
negatively charged with a first pKa1 of 2.12 and a second pKa2 of 7.21 (W.D. Kumler; 
John J. Eiler, 1943). 
 
In the collected reference proteins, neutralization of the charges by coordination of a metal 
appears to be an important factor in the binding mode of phosphate oxygen atoms. 
Magnesium is the metal preferably found in the reference proteins close to POP, ADP and 
ATP, in many cases sandwiched in between oxygens (Figure 22). For AMP, neighboring 
metals differs and there is less metal coordination, which may reflect the lack of 
coordination of the metal by two phosphate atoms (Table 5). Phosphate binding has been 
shown to occur preferentially at phosphate binding cups, which happens often at the 
termini of -helices and takes advantage of helical macrodipoles (Denesyuk & 
Denessiouk, 2003). 
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Figure 22. Distribution of metals less than 3Å of any oxygen atom of (A) POP, (B) AMP, (C) 
ADP, and (D) ATP. 
 
Table 5. Number of metal atoms in the binding sites less than 3 Å from nucleotide oxygen 
atom; in the reference proteins only. 
 
 Reference protein 
 AMP ADP POP ATP 
Metals shared by α/β or β/γ 
(several metals for each complex possible) 
 147 57 
228 (α-/β-P) 
113 (β-/γ-P) 
1 metal in binding site 16 247 21 180 
2 metals in binding site 30 59 18 53 
3 and more metals in binding site 1 23 12 34 
Total with at least one metal 47 329 51 267 
Total reference proteins considered 
 
(dataset studied less filtered than the final 
reference set) 
189 488 92 374 
 
The spatial location of phosphate groups relative to nucleotide base show that the -
pyranose form is likely to be the most predominant, as can be inferred from the Figure 23. 
The spatial location of phosphate groups relative to nucleotide base show that the -
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pyranose form is likely to be the most predominant, as can be inferred from the Figure 23. 
The distance between O3' and the closest oxygen atom bound to the -phosphate group 
suggest that hydrogen bonding between these atoms may occur in a small proportion of 
AMPs (38 out of 282 distance between these heavy atoms less than 3.2 Å) (Fig. 24); this is 
not the case for ADP and ATP and need for further hydrogen bonding may result from the 
relatively smaller number of metals. 
 
 
Figure 23. Superposition of AMP (n= 189), ADP (n=488) and ATP (n=374) in the reference 
structures. 
 
Figure 24. Distribution of the minimal distances between O3' and the closest oxygen atom of 
O1P, O2P or O3P. Data is for (A) AMP; (B) ADP; (C) ATP. 
 
 Local structural replacements 
929 different ligands were extracted using the workflow and data about the 
composition of the different groups is shown in Table 1. LSRs where then extracted and, 
in order to facilitate the analysis and to limit the size of the output, divided into non-
overlapping groups based on the SMILE they contain (Fig.25).  
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Figure 25. Subdivision of the dataset into categories assigned according to the SMILES codes 
of the local structural replacements; a single category is always assigned even 
when several are possible. (A) replacements of α-phosphate of POP, AMP, ADP 
and ATP; (B) replacements of β-phosphate of POP, ADP and ATP, (C) 
replacements of γ-phosphate of ATP; and (D) replacements of ribose of AMP, ADP 
and ATP. 
 
We sequentially attributed ligands to categories, in order: P, presence of letter P in the 
SMILE code, cycle, presence of the number 1 which indicates a cycle, SO2, COO and 
CON, any SMILES compatible with S or C connected to two O, or C connected to O and 
N. The remaining ligands were assigned to four groups, only C, O and N; only C and O, 
only C and N; only C; and what remained. The name of the categories in practice 
corresponds to several SMILES codes, i.e. alternative ways to connect a C atom with two 
O atoms are covered by our methods. 
 
 Phosphate structural replacements 
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Structural replacements found in the context of the ligands are showed in Fig.26. It 
should be noted that the SMILES based classification is exclusive, i.e. the same type of 
replacements can be found in several categories. 
 
Figure 26. The exemplified local structural replacements of phosphate (black) (A) CON (B) 
cycle (C) SO2. All examples are labeled as following ways: ligand three letters or 
digital code (code of protein who complex with the ligand| code of reference 
protein). 
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Phosphorus (P letter) containing SMILES are the most abundant in the sets. Many ligands 
are phosphate containing: nucleotide derivatives (e.g. ligand NAI, LSR containing 
complex 1PJ2/ reference 1GZ3), some with a modified nucleotide base (IMP, 
3ZCT/8GPB), and others are inhibitors (2T6, 3KC1/4GWZ) including ribose-phosphate 
complexes (1GPY/8GPB). More rarely, classical bioisosteres such as phosphonates (e.g. 
AP2, 2VQD/1DV2) or BeF3
-
 (e.g. ONP, 1D0Y/1FMW) ligands are found. Cyclic 
monophosphate replacements can also be found (CMP, 2PW3/1ROR).  
 
In the SO2 category, the larger fragment SO2-NH-CO is very common, for example (SSA, 
1SET/1SES). When mimics occur, hydrogen bonds can be accepted by the oxygen atoms 
but also donated by the NH, a reminder that neutral hydroxyl of phosphate act also as 
hydrogen bond acceptors. The carbonyl is usually not seen mimicking the phosphate, but 
there are exceptions (FG6, 3IVX/2A7X). Other replacements for example sulfonamide, 
are also found (BII, 2JKM/1MP8; 2DD 2BYI/1BYQ). Sulfonate (SO3) can like phosphate 
accept hydrogen bonds (PIN, 1ECF/1ECJ) and also act as a negatively charged 
replacement. Cyclic sulfonamides are found as well (740, 2R64/4I3Z). 
 
Figure 27 A) 3R96, Q47510 (Q47510_ecolx), 1.85; B) 3R9F, Q47510 (Q47510_ecolx), 2.00; 
Water is represented by a red sphere. 
 
In the COO group, compounds are very polar, many containing carboxylic acids, and to a 
lesser extent esters and hydroxyls. On example of different group is dihydrofuran-2(3H)-
one (A51, 2QFO/1BYQ). More surprisingly, otherwise quite hydrophobic example can be 
found (0MA, 2QN2/1FA9). Trimethylglycine, a crystallization agent, has a quaternary 
quaternary amine that goes “on top” of phosphate (BET, 4H5W, 1ATR – BET) and is very 
promiscuous to the dataset. Another basic compound found is another crystallization agent, 
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EDTA, (EDTA, 2AXN/3QPU), whose positive charge is intramolecularly neutralized. The 
other group C+O contains compounds with only C and O atoms inside their LSR. 
Compounds are more diverse than in COO group but appeared to contain less interesting 
examples.  
 
The CON dataset contains peptides/carbamoyls, discussed below, which seems to be good 
mimetic of phosphate. A prevalent example is given by GDM, a cyclic HSP90 inhibitor 
(59c, 4ASA, 1AM1). Often only the carbonyl oxygen is mimicking the interaction of 
phosphate, for example of the ATP -phosphate oxygen (LI8, 1Z5M/1H1W; Z48, 
3I4B/1J1C). In other examples a water molecule is involved in the interaction (ZRK, 
3ZRK/1J1C). Less conventional cases, also found in the CON group, are a tertiary amine 
(methylpiperazine) on top of Pi2 (D42, 2B52/1B39), and a nitro group (XKL, 
4BQJ/1BYQ).  
 
The cycle group represents many interesting possibilities for medicinal chemists. Among 
the cycles, cyclohexane 4SP (2C6O/1B38), imidazole 61K (4FKV/1B38), 
trichlorobenzene (D05, 2B54/1B38), piperazine (D42, 2B52, 1B38), cyclohexaneamine 
(DT4, 2C6L/1B38), triazole (MTW, 2C5Y/1B38) pyrrolidine (2KL, 2WI7/1BYQ) are for 
example found. More surprising replacements are for example cyanuric acid (RDD, 
3BD6/1FA9, an example shown below), ribose (NAI, 1PJ2/1GZ4), morpholine (3Q1, 
3QCS/1H1W), benzene (very good example of superimposition, 3RC, 3RCJ/1H1W), 
nitrophenyl (2XKL, 4BQJ/1BYQ, fluorobenzenesulfonamide (2NQ, 3S2A/1E8X), 
stacking difluoro (PM1, 1PYE/1B38). Tricylic ring system containing tertiary amine (2Q9, 
4O05/1BYQ), and tetracyclic rings with ether or hydroxyl (KWT, 1E7U/1E8X) are also 
found.  
 
The remaining part of the dataset contains tert-butyl (1YG, 4LYN/1B38) for the C only 
set; C+N primary amine KJ2 (2BRE/1AM1) or aniline (5DE, 1YDE/1PTW); for example 
BeS3 (DAA, 1BS1/1A82) or vanadate (VO4, 2QWM/1KAX). 
 Difficulties associated with the categorization 
It is methodologically difficult to define the exact position that corresponds to the local 
structural replacement. I used spheres to identify the space containing these local 
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structural replacements. The first issue comes when the individual atoms of the fragments 
are not well superimposed; the question is then how to define “superimposition” and how 
much “offset” there can be to still have a replacement. This issue is often occurring for 
replacements that are located “half-way” between the ribose and the phosphate (see the 
examples.) In order to address this problem, we used the ShaEP score to eliminate poor 
structural overlaps, but this leads to the smallest replacements to be eliminated from the 
dataset (for example the replacement shown in Figure 28 that will appear later is 
eliminated from the final set because the size of the replacing fragment is too small).  
 
 
Figure 28 Two examples of a non-clearcut definition of local structural replacements (black 
atom carbons). Superimposition of the ligand binding site for ADP (cyan)/ nitro-
containing ligands (yellow) pairs: A) ADP (in 2XK2, 1.95 Å)/ 9UN (in 4B7P, 1.70 Å) 
bound to heat shock protein HSP90, Uniprot code: P07900 (HSP90AA1_human) B) 
ADP (in PDB code: 4I3Z, resolution:2.05 Å)/ Z68 (in 3R9N, 1.75 Å) bound to 
cyclin-dependent kinase 2, P24941 (CDK2_human) The rest of figures abide by the 
same format to protein-ligand contact. 
 
In the first example (Fig. 28a) the para-nitrophenyl moiety is “between” the ribose and the 
phosphate of ADP and therefore it is hard to tell which group the nitro group is going to 
mimic. According to the sphere cutoff criteria, the para-nitrophenyl is within the vicinity 
of both the ribose and the phosphate, but it is a replacement in terms of molecular 
interactions for neither ribose nor phosphate. The non-replaced interactions are: 2'-oxygen 
of ADP hydrogen bonding to nitrogen of Asn106 residue; the phosphate O1A and OA2 
form hydrogen bonds with main chain nitrogen of Phe138 and side chain nitrogen of 
Asn151; when the para-nitrophenyl compound is bound, it forms hydrogen bond between 
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the positively charged Lys122 residue and the electron rich nitro group. The phosphate of 
ADP did not make a charge-reinforced hydrogen bond with adjacent Lys122 residue. 
 
In the second example (Fig. 28b), the meta-nitrophenyl moiety is detected by the 
workflow as “closer” to ribose in terms of distance. However, the meta-nitrophenyl moiety 
is a mimic of the phosphate in terms of interactions, even if this required binding site 
flexibility (induced-fit): the negative charged phosphates are neutralized by the positively 
charged Lys33, while Lys33 and the aryl ring of the meta-nitrophenyl compound are 
within cation-π interaction distance (3.9 Å). This illustrates a very difficult case that is not 
accounted by the method.  
 
Another comment that can be made on the workflow is that the used SMILES sorting is 
quite rough. Some fragments could have been put to several categories, but we preferred 
the option to sequentially sort the SMILES fragments in what we considered the most 
interesting classes (first taking out the least interesting class, i.e. phosphorus-containing) 
and to avoid multiple occurrences. We hope the dataset is in this way more manageable. 
Another issue is the identification of chemical ring structures, which is done by picking 
SMILES fragments with the letter “1”. The sphere cutoff described previously may lead to 
a “truncation” of the molecules; in particular rings that are offset are not detected as such 
in the SMILES codes. We are aware of the problem but solving it is quite complex. 
 
The last concern is a potential bias in the dataset: firstly, e.g. kinases are over-represented, 
which prevents us from making meaningful statistics of the binding site amino acids. This 
issue would require proper sorting of the proteins’ folds. Preliminary attempts with 
sequence-based fold recognition did not succeed. A way to get ahead may be to extract the 
SCOP/Pfam codes from the PDB files for example to sort proteins according to families. 
Secondly, the frequencies of the type of replacements found represent the work of the 
crystallographers and the directions privileged by chemists; it is therefore not surprising 
those well-known replacements such as phosphate and ester/carboxylate look like to be the 
most common. 
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5.2 Previously unrecognized structural replacements of 
phosphate 
As mentioned in the Review of Literature, phosphate groups are highly polar and singly or 
doubly negatively charged groups. In our sample of phosphate groups bound found the 
PDB, a high number of coordinated metals were found (see Fig. 22 and Table 5). 
Previously identified isosteres of phosphate (presented in the Introduction) that conserve 
charge were found to be the most prevalent, without any surprise: for example carboxylate 
or phosphorus-containing replacements (numerical data about occurrence of the relevant 
SMILES code in the dataset is provided in Fig. 25). There are also quite many 
replacements as sulfonyl- or ester-containing compounds. Tetrazole replacements are not 
found in the dataset, but very few tetrazoles are found in the PDB altogether. A summary 
of the pKa values of the common phosphate replacements is presented in Table 6 in grey 
background along with their hydrogen bonding properties (neutral form). 
 
Table 6. Examples of the pKa and hydrogen bonds from data set. Hydrogen bond donating 
(HBD), accepting (HBA), or groups capable of both (HBA/D) are counted for the 
fragments in their neutral forms. Previously known common phosphate isosteres 
are shown with grey background. Fragments are ordered by growing size. 
 
Chemical 
group 
pKa HBA/D only HBA only HBD 
 
AMP 1.54
a
 6.31
a
    
ADP  
ATP 6.5/7.1
a
 
 
0.5-4.76
b
 1 1 0 
 
4.90
i
 0 3 1 
 
>15h 0 1 1 
 
-1.90
c
 1 2 0 
 
10.7
d
 0 2 1 
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2.3
e
 1 2 1 
 
9.48
f
 2 0 0 
 
7.4
g
 1 1 0 
 
 0 0 0 
 
10.64
k
 0 0 1 
 
5.0-6.5
j
 0 2 1 
 
15
l
 0 3 1 
 
6.88
m
 11.40
m
 13.5
m
 3 0 0 
a (Elliott et al., 2012); b http://en.wikipedia.org/wiki/Carboxylic_acid; 
c http://en.wikipedia.org/wiki/Sulfonic_acid; d (Şanli, Şanli, Özkan, & Denizli, 2010); e (Elliott et al., 2012); 
f (Ganellin, 1977); g (Ellis, Palte, & Raines, 2012); h http://en.wikipedia.org/wiki/Amide; i (Satchell & 
Smith, 2002); 
j http://www.cambridgemedchemconsulting.com/resources/bioisoteres/acid_bioisosteres.html 
k (Hall, 1957); l (Sparks et al., 2007); m http://en.wikipedia.org/wiki/Cyanuric_acid. 
 
Table 6 contains also selected examples of the local structural replacements that we found 
more surprising, and that we name here “previously unrecognized” structural replacements. 
These “previously unrecognized” structural replacements could be divided into four 
categories: (1) acidic groups of elevated pKa that in the context of a binding site are likely 
to be ionized (no quantum chemistry calculations are performed in this work, only 
evaluation based on the PDB coordinate); (2) polar non-acidic groups with charge 
delocalization through conjugated  bonds or inductive effects via -bonds; (3) aromatic 
non-polar groups; (4) basic groups. The two last groups represent intriguing possibilities 
to medicinal chemists. How such structural replacements are managed by the binding site 
is illustrated on selected examples below, as well as in Figures 29-32. Figures 29-32 
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illustrate the local structural replacements of phosphate by carbamoyl, carboxycatechol, 
pyridine, and primary amine moieties. The molecular mechanisms of molecular 
recognition discussed in this thesis are summarized in Section V.4. 
 
 
Figure 29 A) 1TBW, P41148 (ENPL_canfa), 2.19 Å; B) 1QY5, P41148 (ENPL_canfa), 1.75 Å. 
Water is represented by a red sphere. All the following figures are labeled as follows: 
the protein is shown as a white ribbon, the concerned amino acids and ligands are 
shown as sticks, the ligands are colored as cyan and the corresponding replacement 
moieties are shown as black. This example was excluded by the empirically set 
ShaEP filter used to compile the final data. 
 
In the dog endoplasmic protein (alternatively named as heat shock protein 90 kDa beta 
member 1, HSP90; Figure 29A), (Soldano et al., 2003), (Immormino et al., 2004), (Dollins 
et al., 2007) two phosphate group distal oxygens of AMP are hydrogen-bonded to the 
amide nitrogen of Asn107 (distance 3.03 Å) and to the main-chain nitrogen of Phe199 
(3.09 Å). In Figure 29B, the phosphate of the AMP analog N-ethyl-5 -´
carboxamidoadenosine has been replaced by a carbamoyl containing fragment. In this 
structure, the carbonyl group of the replacement is not in direct contact with the amide 
group of Asn107, but rather interacts through an intercalated water molecule, which itself 
possibly interacts with the (flipped) amide group of Asn107. In addition, the nitrogen of 
the replacement is within hydrogen bonding distance (3.02 Å) from the main-chain 
oxygen of Asn162. 
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Figure 30 A) 3HW5, Q9Q0U9 (PA_I96A0), 1.81 Å; B) 4E5J, Q5EP34 (Q5EP34_9INFA), 2.35 
Å; magnesium and manganese ions are represented by white and magenta spheres, 
respectively. 
 
The binding site of the influenza A polymerase bound to AMP is highly charged, with 
three negatively and two positively charged amino acids (Figure 30A). The interaction of 
the AMP phosphate is mediated by a magnesium ion as well as a salt bridge to Lys134. 
One water molecule is also involved in this interaction network (Zhao et al., 2009). In 
Figure 30B, carboxycatechol acts as a replacement of the phosphate, while the rest of the 
ligand is different. Two Mn
2+
 ions are found in the X-ray structure; one is coordinated by 
both of the hydroxy groups and the other by one of the hydroxy groups and by the 
carboxyl group. The carboxycatechol moiety likely carries two negative charges since 
chelation by catechol usually happens in their ionic forms (electron withdrawing groups 
enhance ionization of catechols) (Xhaard et al., 2008), (Hikaru Harada, 1971). Other 
residues coordinating the Mg
2+
 are His41, Asp108, and Glu119, as well as Glu80 and 
Asp108 (DuBois et al., 2012).  
 
 
Figure 31 A) 1JBP, P05132 (KAPCA_mouse), 2.20 Å; B) 2F7E, P00517 (KAPCA_bovin), 
2.00 Å. 
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ADP bound to the mouse cAMP-dependent kinase is shown in Figure 31A (Madhusudan 
et al., 1994). The replacement is exemplified by the structure of a bovine ortholog bound 
to a bi-aromatic ligand that contains indole and pyrimidine rings (Figure 31B). The two 
rings are stacked (stacking distance 4.6 Å) in the replacement (Li et al., 2006). The 
proximal phosphate is replaced by the 3,5-substituted pyridine, whose nitrogen atom 
forms a hydrogen bond to Lys72 (2.8 Å). The indole ring is intramolecularly stacked on 
the pyridine ring as well as the Lys72 side chain with hydrophobic interaction. In both 
cases, Lys72 is involved in a charge-reinforced ion paired to Glu91 (2.6 Å). This type of 
replacement is very interesting because there are many occurrences of intramolecular 
stacking of compounds in the dataset, a fraction of which occur at the phosphate binding 
site. In the case presented, adding a ring during study of SARs the preserve the biological 
activity but do not lead to more potent compound. 
 
Figure 32 A) 3QHW, P24941 (CDK2_human), 2.17 Å; B) 1G5S, P24941 (CDK2_human), 
2.61 Å. The magnesium ion is represented by a white sphere. 
 
The last example is cyclin-dependent kinase 2 (Bao, et al., 2011) bound to ADP (Figure 
32A). A magnesium ion is hexacoordinated by two of the oxygen atoms of the phosphates 
(O2A and O1B) as well as by side chain oxygens of the Asn132 and Asp200 residues. The 
primary amino group of Lys33 interacts with both phosphates’ oxygens but it is closer to 
the O1A oxygen. In Figure 32B, the phosphate replacement is a cyclohexylamine moiety 
whose primary amino group sits exactly at position of the magnesium ion, forming a 
charge-reinforced hydrogen-bond with Asp200. Lys85 is pushed away in the replacement. 
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5.3 Structural replacement of ribose 
Of important note, ribose in the context of this study means a ribose linker as found in 
AMP, ADP and ATP, i.e. connected at the 1' and 5' positions. The majority of the ribose 
linkers found in this study is in the β-pyranose form. 
 
A ribose linker is uncharged under normal conditions, and although it is very polar, it 
contains an aliphatic “edge” that can be accommodated in a binding site. This versatility 
seems to be reflected in the variety of groups that we found were able to work as linkers 
(Figure 33). To our best knowledge, ribose structural replacements have not been 
characterized so far, possibly because replacing ribose is less problematic to organic 
chemists than replacing phosphate. Quite often, the ribose is exposed to solvent when a 
nucleotide binding site is a crevice in the protein. Seemingly, the same types of 
replacements could be found for ribose and phosphate. 
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Figure 33. Local structural replacements of ribose (black) (A) CON (B) cycle (C) SO2. All 
example were labeled as following ways: ligand three letter or digital code (code of 
protein who complex with the ligand| code of reference protein). 
 
Three examples of ribose replacements are presented in more detail below: a phenol, a 
series of alicyclics, and an amide.  
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Figure 34 A) 1YXU, P11309 (pim1_human), 2.24 Å; B) 1YXX, P11309 (pim1_human), 2.00 Å 
 
Figure 34 shows the proto-oncogene kinase Pim1 (Kumar et al., 2005). In Figure 34A, one 
water molecule interconnects the AMP ribose 3' oxygen. This water molecule interacts 
with the Phe187 backbone nitrogen, the Glu89 side-chain, and the Lys67 side-chain. 
Figure 34B shows a very conservative replacement of a ribose by a phenol, which is 
mediated by a water molecule. The phenol oxygen takes exactly the same place of the 3'-
oxygen of ribose. 
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Figure 35 A) 3DQX, P00523, (SRC_chick), 2.30 Å; B) 1QPE, P06239, (LCK_human),2.00 Å; 
C) 3EN5, P00523 (SRC_chick), 2.66 Å, D) 3EN4, 2.55 Å, P00523, SRC_chick, E) 
2BDF, 2.10 Å, P12931 (SRC_human), F) 2ZYB, 2.55 Å, P06239,( LCK_human). 
 
Figure 35 shows three types of kinases sharing the same fold, two from human src 
(Dalgarno et al., 2006) and lck (Zhu et al., 1999), (Ozawa et al., 2008) and one being 
chicken c-Src kinase (Azam, Seeliger, Gray, Kuriyan, & Daley, 2008). In Figure 35A, the 
2'-oxygen of ribose is hydrogen bonded to the side chain oxygen of Asp348 via an 
intercalated water molecule. This water molecule is also hydrogen-bonded to the main 
chain nitrogen of Ser345. Figures 35B-E present examples where the ribose is replaced by 
hydrophobic groups, such as tert-butyl (panel B), cyclobutyl (panel C), cyclopentyl (panel 
D), cyclohexyl (panel E) and phenyl (panel F). In panel B and E this water molecule is 
also observed. In panel C and D, water molecules are not found. The reason is probably 
the lower resolution of 2.66 Å in panel C instead of 2.00 Å in panel B. In F, the conserved 
water is not visible but more bulk water is seen. The binding site seems unchanged but 
solvent reorganization seems to accompany the replacements although the somewhat low 
resolution of some examples may prevent a complete understanding.  
 73 
 
 
Figure 36 A) 1TBW, P41148, (ENPL_canfa), 2.15 Å; B) 2GFD, P41148, (ENPL_canfa), 
2.30 Å. 
 
Figure 36 shows the dog glucose-regulated chaperone protein (Immormino et al., 2004). In 
panel A, the 2'-oxygen of the ribose of AMP hydrogen bonds with residue of Asn162 (3.52 
Å) and there is no interaction with Gly196. In panel B, a different ligand is bound and an 
amide replacement of the ribose is shown. The amide nitrogen forms a hydrogen bond to 
the Gly196 main chain carbonyl through a water bridge (3.26 Å with Gly196 nitrogen, 
2.82 Å with Gly198 oxygen) (Immormino et al., 2009). This interaction “pulls” Gly196 
closer to the binding site that likely induce a loop to helix (panel A to B) conformational 
change about the three amino acids (Gly196, Val197 and Gly198).  
5.4 Molecular mechanisms involved in the recognition of local 
structural replacements 
To study the flexibility, the reference binding sites in the reference proteins were defined 
by any amino acid with at least one atom within 4.5 Å of the bound AMP, ADP, ATP or 
POP. Equivalent positions were retrieved based on the sequence numbering in the LSR-
containing proteins, and only when an exact match of all amino acid types occurred 
flexibility could be studied (i.e., only a fraction of the dataset is included here). The result 
shows that while even large loop movements may occur; binding sites typically do not 
undergo generalized changes. (Figure 37) 
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Figure 37. Distribution of the binding sites flexibility for (A-D), all atom RMSD (Å); (E-H), 
Cα-carbons RMSD (Å); (I-L) longest displacement (Å). RMSD are for the datasets 
(A, E, I) POP; (B, F, J) AMP; (C, G, K) ADP and (D, H, L) ATP datasets. 
 
From the examples presented in the previous section, it can be concluded that it is the 
molecular interactions between ligands and binding site residues that anchor the ligand. 
The protein binding sites accommodating ligands are “induced-fit” processes where the 
residues reorganize themselves to host ligands in a favorable way. Different ligands will 
drive residues in different directions; some of them may lead to a minor change of the 
position while others will dramatically be altered. Considering the examples given 
previously in Figures 29-36, as well as our analysis, it is very seldom that the ideal case of 
high conservatively mimic of interactions is seen. The molecular mechanisms that follow 
structural replacements are multiple and may involve: 
 Main chain and side-chain protein conformational change (Figure 36) 
 New interactions mediated by water molecules (Figures 34 and 35) 
 New interactions mediated by metals/ions (Figure 30) 
 Replacement of the ligand by a metal 
o vice versa, replacement of a metal by the ligand (Figure 32) 
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 Replacement of the ligand by a bridging water (Figure 29) 
o vice versa, replacement of a water by the ligand 
 Replacement of the ligand by a fraction of the binding site (Figure 28b) 
 Rearrangement of “bulk” solvent to accommodate hydrophobic groups (Figure 35) 
 Ligand collapse to accommodate hydrophobic groups; intramolecular hydrophobic 
stacking (Figure 31) 
 
For the phosphate groups, local structural replacements seem to be associated with 
preferred mechanisms. The combinations identified in this study are summarized in Table 
7. 
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Table 7. The exemplified structural replacements with preferred mechanisms. 
 
Structural 
replacement 
Structure 
Mechanism in 
the example 
given 
Figure Properties 
benzoxaborole 
 
direct metal 
chelation by the 
boron atom 
(likely ionic 
form) 
- 
acidic with 
elevated pKa 
catechol 
 
direct metal 
chelation 
(likely ionic 
form) 
30  
amide 
 
direct 
replacement 
(mediated by a 
water bridge in 
example) 
29, 36 
polar non-acidic 
groups but with 
charge 
delocalization 
through 
conjugated  
bonds or 
inductive effects 
 
 
hydrophobic 
ligand collapse 
31 
apolar 
aromatic/aliphatic 
  
solvent-facing 
exchange 
  
 
 
the base is 
“replacing” the 
metal 
coordinated by 
the nucleotide 
32 basic groups 
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5.5 Discovery of compounds binding to MDO1 
 
The second part of the thesis deals with the design and synthesis of potentially bioisosteric 
replacements of phosphate-distal ribose of ADPr. This includes ligand based design, 
synthesis, biological activity experiments, and retrospective docking analysis. The 
biological activity experiments were done in Oulu (group of Dr. Lari Lehtiö) using 
differential scanning calorimetry. 
5.5.1 Modeling MDO1 – structural analysis 
When this project started, only the apo form of the human MDO1 was available (PDB 
code: 2X47) but it was not suited for compound design. However, the ortholog structure of 
Archaeoglobus fulgidus bound to ADP-ribose has been reported (PDB code 2BFQ) 
(Karras et al., 2005). A homology model of the bound conformation of human MDO1 was 
constructed based on this template using the software Swissmodeller (Biasini et al. 2014). 
It was denoted as the holo conformation. The model was made such that the crystallized 
ADPr conformation, borrowed from the template, complementarily fit the MDO1 binding 
site (Figure 38B). A pocket is formed by helices 8, 11 and 13, as well as lined by beta 
strands 2, 7 and 8 (Figure 38B). The pocket can be divided into five regions depending on 
the fragments of the bound ADPr that they accommodate (Figure 38C): S1, the adenine; 
S2, the proximal ribose; S3, the proximal phosphate; S4, the distal phosphate; and S5, the 
distal ribose. The macrodomain pocket is L-shaped and the turn occurs in the S2 region. 
 
The major differences between the holo and the apo MDO1 conformations are localized in 
two regions (Figure 38A). Firstly, the S5 sub-pocket is more open in the apo conformation. 
The most flexible loop slice from Gly270 to Phe272 remarkably moved apart from the 
binding site compared to the apo conformation, leading to 4.21 Å variations (RMSD) of 
the main chain. In the holo conformation, the residue of Phe272 flipped down towards the 
binding site and the whole loop also forms a compact space to accommodate ligands. 
Secondly, in the sub-pocket 1, the Phe306 residue (yellow labeled) of the apo 
conformation intersects with the adenosine ring, while it is parallel in the holo 
conformation. In addition, the isopropyl group of the Val183 residue (yellow labeled) 
clashes with the adenosine ring. Hence, in the apo conformation these two residues 
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arranged in a way that the S1 sub-pocket was closed and hence it is not able to bind to the 
adenosine. 
 
 
Figure 38 Three dimensional model of human macrodomain protein 1 (MDO1) complexed 
with ADPr. (A) Structural superimposition of the apo (cyan, PDB code: 2X47, 
Val183, Phe306. Phe272, yellow) and holo (homology model, white) states. (B) 
Schematic presentation of the holo ADPr binding site. (C) The surface of the holo 
state’s binding pocket. Green dash eclipses label the individual subpockets from S1 
to S5. (D) Detailed stereo view of the interactions at the ADPr binding site of the 
holo state. Green dash lines represent the hydrogen bonding. 
 
The interactions of ADPr with MDO1 is depicted by Figure 38C-D. The S1 region 
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accommodates the adenine ring. The purine ring is sandwiched between the planar phenyl 
group of Phe306, interacting with π-π interaction, and the aliphatic side-chain of Val183. 
The NH2 group of adenine (N6) is donating a hydrogen bond to the side chain carboxyl 
oxygen of Asp160. In addition, the N1 nitrogen from the Watson-Crick edge of adenine 
accepts a hydrogen bond from the main-chain nitrogen of Ile161. The S2 region holds the 
proximal ribose. The proximal ribose is surrounded by Pro265, Asp310, Cys266 and 
Thr269. O3' of the ribose donates a hydrogen bond to the side-chain of Thr269. The S3 
region accommodates the proximal phosphate, which has a first pKa of 1.54 and therefore 
is likely to be negatively charged. The negative charge of the phosphate is neutralized by 
the positively charged macrodipole at the N-terminus of helix 8. This macrodipole is 
generated by the sum of the dipolar contributions from the helical backbone. In addition, 
on the top of this helix, the NH groups of Val183 and Gly182 main-chain donate the 
hydrogen bonds to oxygen of the phosphate. In the S4 region, the distal phosphate is 
trapped by a part of the turn, which links beta strand 7. Specific hydrogen bonds are also 
formed between the amide nitrogen amino acid Ser268, Gly270 and Val271. The distal 
ribose moiety attached to the distal phosphate group is located in the S5 region, which is 
formed, by Asn174, Asp184, Gly181 and Phe272. The O1' and O2' of ribose donate 
hydrogen bonds to the main-chain nitrogen of Gly181as well as to the side-chain of 
Asn174 and Asp184 respectively. In addition, the side-chain of Phe272 is close to the 
ribose. 
5.5.2 Synthesis of ADP analogs 
To investigate how phosphate isosteres are accommodated at the MDO1 site 
experimentally, we designed a set of ADP analogs. Among these analogs, we kept the 
adenosine and ribose moieties unchanged while the phosphates were replaced by potential 
bioisosteres, linking variety of substituents. The phosphate replacer can be regarded as a 
linker. Two series of analogs were designed: the squaryldiamide (Scheme 1) and the amide 
(Scheme 2 and 3) series. Nine compounds are based on a squaramide linker and six 
compounds based on an amide linker. At the beginning of the study, besides these two 
series, I also planned a series of compounds with sulfonamides as mimics of phosphate, 
(Gajewiak & Prestwich, 2006), (Dong et al., 2010) but these were not prioritized and were 
not synthesized. 
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5.5.2.1 Chemistry 
 Scaffold 
We started on the synthesis of the target compounds by treating diethyl squarate (4) with 
various aliphatic, aromatic and benzylic amines in ethanol to give nine differently 
substituted alkoxy amino squarates (5-13) in good 71-92% yield (X. Zhang et al., 2013). 
Only mono-substituted products were formed in this reaction. (Niewiadomski et al., 2010) 
In a similar fashion, the acetonide-protected 5 -´amino-5 -´deoxyadenosine (3) was reacted 
with the alkoxy amino squarates 5-13. This transformation produced the acetonide-
protected and unsymmetrically 3,4-substituted cyclobut-3-ene-1,2-diones 14-22 that were 
subsequently deprotected in the presence of aqueous trifluoroacetic acid (TFA) to give a 
set of nine different 3-(5 -´amino-5 -´deoxyadenosine)-4-(alkylamino)cyclobut-3-ene-1,2-
diones (23-31) in 83-90% yields. 
 
 Squaryldiamide series.  
Squaric acids and squaryldiamides have been reported as bioisosteres of phosphate (Seio, 
Miyashita, Sato, & Sekine, 2005) though have not been that successful so far (Moreau et 
al., 2013). I synthesized nine ADP analogs using squaryldiamide as a linker/core. 
Adenosine is on the one side of the asymmetrical squaryldiamide, and on the other side 
different substituents were attached, such as n-butyl, phenyl, benzyl, pyridin-4-yl-methyl 
and 5-methylfuran-2-ylmethyl with the aim to exploit optimal interactions. Purification of 
the final products were problematic with SiO2 column chromatography but amine 
functionalized SiO2 columns (NH-KP, Biotage) allowed us to successfully purify the 
synthesized compounds. 
 
The compounds of the first series, squaryldiamides 23-31, were synthesized in three 
reaction steps starting from diethyl squarate (4) and two different amines (Scheme 1). First, 
the key building block, acetonide-protected 5'-amino-5'-deoxyadenosine (3) was 
synthesized. We treated 2',3'-O-isopropylideneadenosine (1) first with diphenylphosphoryl 
azide (DPPA) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and subsequently with 
sodium azide and 1,4,7,10,13-pentaoxacyclopentadecane (15-crown-5) in 1,4-dioxane 
under reflux to yield acetonide-protected 5'-azido-5'-deoxyadenosine (2) in 92% yield. 
Subsequently, the azido intermediate (2) was converted to the desired key building block 
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(3) by using a modified Staudinger reaction in the presence of polymer-bound 
triphenylphosphine. (Ayesa, Samuelsson, & Classon, 2008) Acetonide-protected 5'-amino-
5'-deoxyadenosine (3) was obtained in 70% yield. 
 
Scheme 1. Synthesis of the squaryldiamide series.
a 
 
a Reagents and conditions: i) DPPA, DBU, NaN
3
, 15-crown-5, 1,4-dioxane, rt to 110 °C, overnight, 92%; ii) triphenylphosphine (polymer-bound), THF, H
2
O, rt, 4 h, 
70%; iii) amine, EtOH, 0 °C to rt, 2 h, 71-92%; iv) DIPEA, EtOH, rt, 5 h to overnight, 79-91%; v) TFA/H2O (4:1), rt, 5 h, 83-90%. 
 
 Amide series 
Six amide-linked ADP analogs were synthesized. Compound 37 was aimed at validating 
the similarity of hydrogen bonding between phosphate and hydroxy, while compound 38 
contains a carboxylate group designed to examine the charge similarity to ADPr. The 
Fmoc-protected compounds 34 and 36 were also tested in order to find a fluorescence 
marker of that protein to facilitate screening. They are the precursors of 37 and 38. 
Tetrazole is a bioisostere of the carboxyl group while the carboxyl group is able to 
structurally replace phosphate; that was the motivation to synthesize compound 41, and as 
a negative control compound 42. 
 
The synthesis of the amide series was started by coupling amine 3 with N-
hydroxysuccinimide (OSu)-activated ester and fluorenylmethoxycarbonyl (Fmoc)- and 
tert-butyl protected amino acids (Fmoc-Ser(tBu)-OSu and Fmoc-Asp(OtBu)-OSu, 
respectively) to give compounds 32 and 33 in 76 and 75% yields, respectively (Scheme 2). 
Deprotection of the acetonide- and the tert-butyl groups of compounds 32 and 33 was 
performed by a mixture of TFA/H2O/CH2Cl2 (5:1:4) to give the Fmoc-protected amino 
acid derivatives 34 and 36, both in 90% yield. The serine derivative 37 was obtained in 43% 
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yield after deprotection of the Fmoc group with diethyl amine (DEA) in N,N-
dimethylfomamide (DMF). The aspartic acid analog 38 was prepared with a different 
deprotection strategy. First, the Fmoc group of 33 was deprotected with DEA in CH2Cl2 
giving the amine 35 in 59% yield. Subsequently, the rest of the protecting groups of 
compound 35 were removed with TFA/H2O/CH2Cl2 (5:1:4) to give the product 38 in 81% 
yield. 
 
The peptide coupling reactions to prepare compounds 37 and 38 were conveniently 
performed with OSu-activated amino acids. Commercially available OSu-activated 
starting materials were not available for compounds 41 and 42. Therefore, HBTU was 
used as a coupling reagent of the starting material carboxylic acids in these reactions. 
 
Scheme 2. Synthesis of the amino acid series.
a
 
 
a Reagents and conditions: i) Fmoc-Ser(tBu)-OSu or Fmoc-Asp(OtBu)-OSu, MeOH, rt, 2 h, 75-76%; ii) TFA/H
2
O/CH
2
Cl
2
 (5:1:4); rt, 5 h, 59-90%; iii) DEA, CH
2
Cl
2
, 
rt, 2 h, 59% yield; iv) DEA, DMF, rt, 2 h, 43%. 
 
In the syntheses of the two tetrazole analogs 41 and 42, amine 3 was first reacted with 
either 1H-tetrazole-5-acetic acid or [(1-phenyl-1H-tetrazol-5-yl)thio]acetic acid using 
N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate (HBTU) as 
a coupling reagent to yield the amides 39 and 40 in 80 and 85% yields, respectively 
(Scheme 3). Subsequently, the acetonide-protecting groups of amides 39 and 40 were 
removed with TFA/H2O/CH2Cl2 (5:1:4) to give the products 41 and 42 in 83 and 77% 
yields, respectively. 
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Scheme 3. Synthesis of the tetrazoles.
a 
 
a Reagents and conditions: (i) 1H-tetrazole-5-acetic acid or [(1-phenyl-1H-tetrazol-5-yl)thio]acetic acid, HBTU, DIPEA, DMF rt, 4 h, 80-85%; (ii) 
TFA/H
2
O/CH
2
Cl
2
 (5:1:4), rt, 5 h, 77-83%. 
 
 Purification  
For most of the compounds, the final step of purification was always a challenge since the 
compounds are really hydrophilic. When the reaction mixture was loaded to a normal 
phase silica column, the required products remained adsorbed to the column even though a 
high concentration of methanol was used in the eluent. For the purification process to 
work a maximum of 20 % of methanol in chloroform was found to be practical. 
percentages of methanol can dissolve the silica present in the column. Theoretically, 
organic solvent mixtures of acetonitrile, ethyl acetate, or even DMF could be used with a 
higher methanol concentration. I also used preparative and reverse phase HPLC columns 
to purify very polar compounds. In this study, I obtained the pure compounds 37, 38 and 
41 through this method. Preparative reverse phase HPLC columns suffer from the 
drawback that the loading is very low. For the mild polar compounds, such as compounds 
29 and 30, I used instead an amine-functionalized silica column (NH-KP, Biotage) to 
successfully purify the final compounds. 
5.5.2.2 Biological activity 
Within the squaryldiamide series, three compounds were active: the benzyl-substituted 
compound 26 as well as the phenyl-substituted ones 27 and 28. The two phenyl-
substituted compounds were found to be the best stabilizers (Table 8). The compounds 
with a 3-nitro (compound 27) and a 4-methoxy (compound 28) substituent have a ΔTm of 
0.78 °C and 0.77 °C, respectively. This is comparable to the Tm-shift observed for ADP 
(0.69 °C). Among the benzylic compounds, the 4-fluorobenzyl derivative (compound 26) 
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showed a comparable Tm-shift value to AMP (0.47 °C and 0.41 °C, respectively). This 
indicates that a shorter distance between the adenosine and the aromatic ring is favorable 
for binding, while additional nitro and methoxy substituents seem to result in equipotent 
binding. In addition, comparing the structures of the fluoro-substituted benzyl derivative 
(compound 26) with the unsubstituted benzyl derivative (compound 23), compound 23 
was not able to stabilize human MDO1. This indicates that activity is gained by the 
addition of a fluorine atom to the benzylic substituent. The remaining compounds of this 
series (24, 25, 29 and 30) did not show stabilization and thus binding. Activity of 
compound 31 could not be determined due to unspecific high fluorescence in the assay. 
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Table 8. Docking scores and Tm-shift assay results of human MDO1 for the compounds of 
the squaryldiamide series.a 
 
Compound R 
Docking 
score 
Tm/ºC ΔTm/ºC 
- -  47.80 0 
AMP - -9.16 48.21 0.41 
ADP - -10.54 48.49 0.69 
ADP-ribose - -14.80 53.54 5.54 
23 
 
-10.53 47.55 -0.25 
24 
 
-10.75 47.87 0.07 
25  -10.78 47.80 0 
26 
 
-12.08 48.27 0.47 
27 
 
-9.45 48.58 0.78 
28 
 
-9.86 48.57 0.77 
29 
 
-10.33 47.89 0.09 
30 
 
-8.71 47.85 0.05 
31 
 
-12.55 N.D. N.D. 
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a The T
m
-shift assay was performed as described in the experimental section and the associated results are expressed as mean values. Compounds were tested at 1 
mM concentration. Docking scores were obtained by the XP scoring function (Schrödinger Ltd) as described in the experimental section. The lower the value, the more 
favorably the ligands bind. N.D. = not determined (unspecific interaction resulting in high fluorescence). 
Table 9. Docking scores and Tm-shift assay results of human MDO1 for the compounds of 
the amide and tetrazole series.a 
 
Compound R 
Docking 
score 
Tm/ºC ΔTm/ºC 
34 
 
-9.26 48.38 0.58 
36 
 
-11.45 48.55 0.75 
37 
 
-8.91 47.66 -0.14 
38 
 
-10.47 47.91 0.11 
41 
 
-9.88 47.67 -0.13 
42 
 
-9.94 47.59 -0.21 
a The T
m
-shift assay was performed as described in the experimental section and the associated results are expressed as mean values. Compounds were tested at 1 
mM concentration. Docking scores were obtained by the XP scoring function (Schrödinger Ltd) as described in the experimental section. The lower the value, the more 
favorably the ligands bind. 
In the amide series, the Fmoc-protected amino acid derivatives of L-serine (compound 34) 
and L-aspartic acid (compound 36) stabilized the protein, with Tm-shift values of 0.58 °C 
and 0.75 °C, respectively (Table 2). Only a negligible stabilizing ability of 0.11 °C was 
observed when the Fmoc group was removed (compound 38). This means that the large, 
aromatic and flat tricyclic Fmoc group contributes to binding. Compounds with carboxyl 
groups (36 and 38) clearly retained a better activity than their hydroxy counterparts (34 
and 37). This indicates that the carboxyl group is a better substituent than hydroxy, likely 
due to its negative charge. 
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We could not successfully estimate the KD for the compounds studied here using 
isothermal titration calorimetry (ITC, data not shown), perhaps because their activity is 
weak, in the μM range. The ΔTm values of the benchmark ligands at 1 mM concentration 
for human MDO1 are the following: AMP, 0.41 °C; ADP, 0.69 °C; ADPr, 5.54 °C. The 
ADPr KD of 0.9 μM has been measured using ITC,(Neuvonen & Ahola, 2009) and ADPr 
causes the largest Tm-shift in the DSF assay. Similar ΔTm of 5.98 °C (at 2 mM) and KD of 
5 μM have been reported for ADPr in the viral chikungunya macrodomain protein.(Malet 
et al., 2009) (The chikungunya macrodomain protein would bind ADP better than human 
MDO1, with ΔTm of 4.88 °C for ADP and 0.34 °C for AMP at 2 mM). 
5.5.2.3 Docking analysis 
We next focused the analysis on the active compounds 26-28, 34 and 36, and we 
hypothesized that these compounds interact with human MDO1 in the same 
conformational state as ADPr. A preliminary study showed that the structure of MDO1, in 
the apo form, is not suitable for accommodating ADPr, since especially the side chain 
conformations of Phe306 and Val183 prevent docking. Therefore, a homology model of 
the human MDO1 protein based on Af1521 was used instead. The binding site in the 
human MDO1 model could favorably form suitable interactions with ADPr. The binding 
mode of ADPr extracted from the crystal structure of Af1521 can be successfully 
reproduced in the structural model of human MDO1 using docking with GlideXP (Figure 
38D). The set of compounds was then docked to the model using Glide and the XP scoring 
function (Tables 8 and 9). ADPr has the best score of all, while compounds 26 and 36 that 
are good stabilizers have the second and third best scores, respectively. Otherwise there 
seems to be little correlation between the docking scores and the measured thermal shifts, 
but docking scores are notoriously poor indicators of binding affinities. 
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Figure 39. Predicted binding modes of human MDO1 in complex with (a) ADPr, (b) 26, (c) 27, 
(d) 28, (e) 34 and (f) 36. Carbon, oxygen, nitrogen and fluorine atoms are shown in 
black, red, blue, and light blue, respectively. The white cartoon represents the 
protein, and the carbon atoms of binding site residues are showed in cyan. Putative 
hydrogen bonds are depicted as dashed lines in green. 
 
Next we will focus on the analysis of the most active compounds 26-28, 34, and 36, 
considering only the best-ranked pose. For all these compounds, the adenine ring and the 
ribose occupy the same position as the position predicted for ADPr (Figure 39). The 
purine ring is sandwiched between the planar phenyl group of Phe224 (π-π interaction) 
and the aliphatic side-chain of Val183. The NH2 group of adenine (N6) is donating a 
hydrogen bond to Asp160. In addition, the N1 nitrogen from the Watson-Crick edge of 
adenine accepts a hydrogen bond from the main-chain nitrogen of Ile161. The proximal 
ribose is surrounded by Pro265, Asp310, Cys266 and Thr269. The hydrogen of the ribose 
O3' hydroxy group donates a hydrogen bond to the side-chain of Thr269. 
 
We next examined which groups are docked in place of the proximal phosphate of ADPr 
(Figure 39). In MDO1, the negative charge of the proximal phosphate is neutralized by the 
positively charged macrodipole at the N-terminus of helix 8 (Figure 38b). This 
macrodipole is generated by the sum of the dipolar contributions from the helical 
backbone. In addition, on the top of this helix, the main chain NH of Val183 donates a 
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hydrogen bond to an oxygen atom of the proximal phosphate. Similarly to the phosphate 
groups of ADPr, the carbonyl of the carbamate group in compound 34 forms a hydrogen 
bond with the main chain of Val183, while the NH of the carbamate group of compound 
36 is in a suitable position to accept a hydrogen bond from the main chain carbonyl of 
Ala172 (Figures 39 e and f). For compounds 26-28, the two amide NH groups of the 
squaryldiamide moiety docked approximately at the position of the proximal phosphate of 
ADPr (Figure 39 b-d). The hydrogen bonding interactions seen in ADPr are however not 
recreated: in compound 26, the distal amide NH of the squaryldiamide forms instead a 
hydrogen bond with the main chain carbonyl of Ala172, whereas the amide hydrogen 
bond donors do not seem satisfied in compound 27 and 28. Water molecules do play 
important role in molecular recognition and may bridge these hydrogen-bonding groups, 
although they are not included in the docking simulation. On the other hand, it is possible 
that a next generation of compounds could be designed that contain a hydrogen-bond 
acceptor pointing towards the main chain NH groups of Val183 and Gly182. 
 
In ADPr, the distal phosphate is hydrogen-bonded to the main chain NH of Ser268, 
Gly270 and Val271 (Figure 39a, Gly270 is not shown). In compounds 26-28, one of the 
squaryldiamide oxygen atoms is located approximately in the same position as one of the 
oxygen atoms of the distal phosphate, able to hydrogen bond with Ser268 and Gly270, but 
not Val271. In compounds 34 and 36, both the carbonyl of the amide linker and the 
oxygen of the hydroxy and carboxyl groups are well placed to mimic the interactions of 
the distal phosphate, making hydrogen bonds with the main chain NH of Ser268. Our 
compounds thus seem to make suitable hydrogen bonds at position equivalent to the distal 
phosphate. 
The third part of ADPr that is mimicked is the distal ribose. In ADPr, the distal ribose is 
surrounded by Asn174, Asp184, Gly181 and Phe272. The O2' and O3' of ribose form 
hydrogen bonds to the main chain NH of Gly181 as well as to the side chain of Asp184. In 
addition, the side chain phenyl of Phe272 is close to the ribose, making hydrophobic 
interactions with the non-polar edge of the ribose. For compounds 26 and 27, the nitro- 
and fluoro-substituted phenyl rings are similarly located; these aryl substituents are thus 
well placed to make T-shaped stacking with Phe272 as well as edge-to-edge interactions 
with Asp184. It is possible that the interaction of 28 with Phe272 is less optimal. For 
compounds 34 and 36 that contain the tricyclic ring of Fmoc, one ring is coming “on top” 
 90 
 
of the docked aryl of Phe272 as well as the distal ribose, with the tricyclic ring stacked 
between Gly181, Val271 and Phe272. Based on these docking results, it seems that the 
distal ribose can be replaced by aryl moieties and that there is enough space to 
accommodate a tricyclic ring in the binding pocket of the human MDO1. 
5.6 Virtual screening approach 
This last section is divided into three parts. (1) Selection of potential compounds to be 
tested using “functional analogy” (i.e. ADP binding) and PCA for selection. Compounds 
were purchased from Tocris Bioscience (Bristol, United Kingdom). These are later 
referred to as TOCRIS compounds (13 molecules). (2) Selection of potential compounds 
to be tested using structure-based virtual screening. Compounds were purchased from the 
Chembridge Corporation (San Diego, United States of American). These are later referred 
to as Chembridge compounds (30 molecules). (3) Experimental testing: three experiments 
were used: competition assays and ITC and DSC calorimetry.  
 
 Selection of compounds based on functional similarity 
We hypothesized that compounds binding to an ADP site in a different protein may 
show cross-binding to MDO1. The hypothesis is that ligands maybe also fit in a macro 
domain if they fit in ADP site of another protein. 
 
Under this hypothesis, we selected a small dataset of 43 ligands directly from the 
TOCRIS catalog: 
- adenosine receptors ligands (9 agonists and 14 antagonists) 
- P2Y receptors (3 agonists and 10 antagonists, 1 unknown) 
- 6 methyltransferase inhibitors. 
 
All ligands were put into force field to perform energy-minimization. Ligands with a 
phosphate and a carboxyl group were deprotonated manually. The structures of the ligands 
were prepared in Sybylx12. 
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Principal component analysis (conducted with the software Volsurf+ based on 
Volsurf+ 122 descriptors) was used to map the chemical space of these compounds. The 
result is shown in Figure 40. ADPr is shown in green and in the PCA it comes near other 
adenosine analogs. 
 
Based on PCA analysis of the space, 13 compounds from the Tocris catalog were 
suggested to be tested for biological activity. The 13 compounds represented by a red dot 
were selected for experimental testing. 
 
Figure 40. Distribution of the 13 selected ligands among the 43 selected from the TOCRIS 
catalog (principal component analysis, PC1 and PC2), the selected compounds are 
marked with a red dot. 
 
 Selection of compounds based on virtual screening 
The FIMM library, owned by the Institute for Molecular Medicine Finland (FIMM), 
approximately contains 20,000 lead like compounds. All compounds are available in stock 
in different amounts. It is our primarily chosen library because it is very convenient to 
purchase and test compounds from this library. The ligand structures were prepared from 
2D .sdf-files to 3D using Balloon (Vainio & Johnson, 2007). 
The FIMM library was docked to the holo homology structure model of MDO1 (the same 
model as in Figure 37A) with GOLD 5v2. By default, ten results are available and the 
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solution with best (highest) score was selected as the most favorable binding mode of 
ligands. The α-carbon of Val183 was defined as docking center with 20×20×20 grid box. 
The top 200 of the Gold scores were selected for further analysis. Figure 32 summarizes 
the docking result. ADPr was used as a control and it obtained the best score; we are very 
limited because we this is the only control available. 
Sixty compounds were chosen manually with visual inspection and in collaboration by a 
medicinal chemist and based on criteria for example: 1) up to two hydrogen bonds in the 
adenine binding subpocket; 2) a “bend” in the molecule; 3) the proximal ribose in polar 
surrounding; 4) hydrogen bond acceptors/donors at the phosphate subpockets. From this 
set of sixty compounds, we purchased thirty compounds from the Chembridge 
Corporation taking into account a maximum molecular diversity and the lowest possible 
price. 
 
Figure 41. The Gold docking scores of top 200 FIMM compounds. 
 Experimental testing 
Based on the ADPr and PolyADPribose competition assay (Figure 42, Table 10), five 
compounds from the Tocris set showed inhibition from 41 to 67%. Six compounds from 
the Chembridge set showed inhibition from 28 to 67% (see Table 10). Poly-ADPr 
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competition assay was also done for all chosen compounds (see also Table 10). Some of 
the results do not consist with the results from the ADPr testing. For example, the Tocris 
candidate MRS 2578 replaced 67% of ADPr, but only 8% of Poly-ADPr. The structures of 
all active compounds are showed in Figure 43. 
 
 
 
Figure 42. Activities of the 43 compounds tested using ADPr and PAR competition binding 
assays. 
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Figure 43. The structures of compounds, which showed activity in the ADPr and poly-ADPr 
competition assays. 
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Table 10. Biological activities of the most active compounds in either ADPr or PAR 
competition assays. 
Compounds ID vendor 
Percent 
inhibition 
(ADP-
ribose)(200 
nM) 
Percent 
inhibition 
(poly-ADP-
ribose)(20 M 
Tested with 
DSC at 10 μM 
Tested with 
DSC at 100 
μM 
RG 108 Tocris 43 2 Inactive Inactive 
MRS 2211 Tocris 48 96 Inactive Inactive 
MRS 2578 Tocris 67 8 Inactive Inactive 
VUF 5574 Tocris 51 10 Inactive Inactive 
PPADS Tocris 41 94 - - 
5213180 Chembridge 62 43 Inactive - 
6593249 Chembridge 34 47 Inactive - 
6991066 Chembridge 29 38 - - 
5672011 Chembridge 28 36 - - 
7118821 Chembridge 34 57 Inactive - 
7159230 Chembridge 43 51 Inactive - 
 
The main conclusion of the experimental testing was that some of the compounds were 
found active in the ADPr competition assay. However, the assay was not optimized and 
there were doubts whether the activities were a result of artefacts (ligands inducing the 
protein to leave its support), leading to false positive results. Furthermore, comparing the 
results for the ADPr and PAR assays looked inconsistent. Consequently, the compounds 
were retested using DSC and ITC and at that time, no activity was found at the compound 
concentration (10-100 M) used. During the writing of this thesis, it came out that the 
compound concentrations used in the assays were too small for detection – at 100 μM we 
cannot either detect the ligands synthesized. This led to the decision that the compounds 
should be retested using a higher concentration, and therefore, we cannot conclusively 
make a statement about their activities. 
 
  
 96 
 
6 Perspectives 
In this study, the motivation to exemplify the structural replacement of phosphate is as 
following: 1) phosphate is critical in biological systems; 2) to make our result statistical 
meaningful, we need enough of data points. In that sense, phosphate is a good candidate 
because it is widely observed in endogenous ligands. To the best of our knowledge, there 
are no published studies dealing with the replacement of ribose, while total synthesis of 
pentose ring is not that easy.  
 
In order to reach medicinal chemists, we have designed a searchable web server. Work 
is under progress and the website may be functional at the time of defending the thesis. 
The data generated has been placed on a cloud-based website architecture linked to a Jmol 
plugin for consultation (written in php Java script an XML), and can also been 
downloaded from there in part on its in entirety http://86.50.168.121/phosphates_LSR.php 
(accessible December 4
th
, 2014). 
 
 Practical use of the structural replacement study 
Phosphate is a common endogenous substrate in biological systems and a lot of proteins 
have natural affinity to it. A typical example is pyrophosphatase, which couples 
pyrophosphate hydrolysis or synthesis to Na
+
 or H
+
 pumping. This protein was the first 
membrane protein structure ever solved and published in Finland (PDB codes: 4AV3 and 
4AV6) (Kellosalo, et al., 2012). It is one main application of my study on structural 
replacements, and very interesting preliminary results have been obtained. The issue I very 
soon faced in that project is that chemical libraries useable for virtual screening seldom 
contain compounds that are focused for a phosphate site, i.e. contain polar and potentially 
charged groups. Molecules obtained directly from virtual screening did not look promising. 
I therefore used two strategies for compound selection: the first one was to develop filters 
that were used to focus the library to fragments identified as isosteres of phosphates, for 
example the 1,2,5-thiazolidin-3-one-1,1-dioxide. The second was to directly select 
compounds from vendor catalogs. This second approach has actually revealed some hit 
compounds with validated binding affinity. 
  
 97 
 
Generalizing and improving the automated workflow 
 
The workflow presented in the thesis could be generalized to exploit structural 
replacements of other chemical fragments by giving different substructure queries. 
However, this methodology has limitations; 1) the need of many ligands in the PDB 
(otherwise we cannot confidently state that one group can replace a target fragment); 2) 
both the reference and the superimposed protein structure should be in the PDB. For 
example, tetrazole is a well-known isostere of the carboxyl group while carboxyl groups 
and phosphates are interchangeable. Thus it can be speculated that tetrazoles can replace 
phosphates as well, but we did not find such examples simply because there is not enough 
data points in the PDB. 
 
Another perspective is to develop and generalize the automated workflow to other 
moieties than phosphate and ribose, for example to peptide/ amide bonds. There are biases 
in the dataset which have to be taken into consideration, for example we did not consider 
the individual structural replacement preference against protein family. In our study, it is 
no surprise that kinases and heat shock proteins dominate the population of our dataset 
because phosphate is a very common building block of their endogenous ligands. The 
solution is to cluster proteins into family classes given the protein Uniprot identifier 
according to Structural Classification of Proteins algorithm. (Andreeva et al., 2008)  
 
Designing better MDO1 ligands 
 
Based on literature as well as our isosteric replacement study of both phosphate and ribose, 
we discovered many chemical moieties that are able to replace phosphate or ribose in 
specific circumstances, such as amide and heterocyclic groups. In this thesis work, I have 
validated the amide and squaryldiamide groups as isosteric replacements of phosphate. 
Among 15 synthesized adenosine analogs, the binding of four were comparable to ADP 
and one to AMP.  
 
We explored the substitution of the phosphate-distal ribose part of ADPr. The next step 
would be to substitute the adenine-proximal ribose part of ADPr, for example using 
potential ribose replacements found in this thesis. We have not tested our findings of 
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ribose isosteric replacement. As a continuation of this project, it would be worth combing 
both the phosphate and ribose isosteric replacements we have found. Subsequently, novel 
compounds differing from ADP could be developed. Even if it has not been tested, our 
ligands could be speculated to be bind to other proteins. Changing the adenine part should 
also improve the specificity of our ligands towards MDO1.  
 
Another area is to improve the potency of our ligands. Based on docking, new derivatives 
can be synthesized to further optimize the protein-ligand interactions. For example, an 
interaction with helix 8 can be an option since the α-helical dipole putatively exists 
(Sengupta et al., 2005) and it is critical to phosphate binding, but there is no hydrogen-
bond acceptor in my compounds. We could for example develop a compound with a cyclic 
moiety, e.g. a cyclopentane-1,3-dione, with two branched carbonyl that may form a 
backbone hydrogen bond of both helix 8 and turn 7. In addition, more optimization can be 
performed on the most distal part of the molecule. Here we could take advantage of the 
flexibility of the turn 8 and to prepare compounds with substituents of different sizes. This 
would allow us to develop compounds that do not occupy the adenine-proximal ribose 
binding site, since we do not want to make very large molecules in the end. 
 
What’s more, we have discovered a potential binding location that can favorably accept a 
tricyclic rings. We could now try to place for example fluorescein to develop a fluorescent 
probe useful for screening. According to our collaborator, even a low-potency probe 
would be useful. It was surprising and counter-intuitive that Fmoc was accommodated by 
the binding site since it is a large substituent. 
  
Retesting the virtual screening hits with thermofluor  
 
The results of the virtual screening study I performed with the purpose of finding new 
ligands for human MDO1 (see chapter V.6.) are not conclusive so far; activity of the 
compounds was found by the competition assay but no activity by the preliminary 
calorimetric study. However, the concentration of the compounds used for testing in the 
calorimetric method was outside of the detection window, i.e. they should have been in the 
mM range instead of in the μM range. Thus, these molecules should be retested at mM 
concentrations.  
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Concluding remarks 
 
As a general perspective, my study not only validated the variety of local structural 
replacements, but also suggested additional possibilities. In addition, the conditionality of 
these surrogates is emphasized, since replacements are circumstance (binding-site) 
dependent. One isosteric replacement validated in one binding site cannot directly be 
translated into another. In terms of the synthetized compounds, the ones containing a 
carboxyl group were surprisingly found not to increase the binding to MDO1. The 
squaryldiamide and amide groups were both useful isosteres of phosphate. The most 
surprising is that the major determinant of potency was found in the presence of 
hydrophobic groups, i.e. the compounds containing a phenyl or benzyl group and the 
presence of the Fmoc group. Our study thus emphasized the versatility of mechanisms that 
accompanies structural replacements; they all blur the definition of “structural similarity” 
presented in the Review of Literature and as the “Structure-Property-Principle”, since 
these two concepts are based in the conservation of molecular interactions. 
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